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I - I N T R O D U C T I O N 
 
1.1 Glomerular Mesangial Cells – physiological functions, pathological implications 
The nephron is the smallest functional unit of the kidney. It consists of the glomerulus, the 
proximal tubule, the loop of Henle, the distal tubule and the collecting duct. The glomerulus 
includes the blood vessel bundle between the afferent and efferent arteriole. But it also 
integrates the capsule of Bowman with all its interior and is used equivalently to the 
malphighian corpuscle. The mesangium is the intercapillary space within the glomerulus. 
Under physiological conditions only fluids or molecules smaller than 5-10 kDa enter the 
Bowman space freely. Larger components of the blood are effectively restrained by the 
glomerular barrier, which is composed of three sheets: the fenestrated endothelium of the 
arterioles, the glomerular basement membrane (GBM) and slit pores between foot structures 
of podocytes. But not the entire capillary surface is covered by the GBM, a certain part is 
enclosed by mesangial cells (MC) or MC-derived extracellular matrix (ECM). MC are smooth 
muscle-like pericytes, which modify the capillary surface area and thus contribute to the 
regulation of the glomerular filtration rate (GFR) (Stockand and Sansom, 1998).  
The function of MC is not only restricted to mechanical or statical work, they participate also 
in immunological affairs and even have phagocytic function (Schlondorff, 1987). 
MC built up one-third of the total number of glomerular cells in a normal adult kidney but the 
number of MC may alter under pathological conditions (Pabst and Sterzel, 1983). MC are 
able to respond to and to produce themselves mediators that induce MC proliferation and 
deposition of ECM (Pabst and Sterzel, 1983) – two characteristics of many inflammatory 
kidney diseases.  
MC hyperplasia can be found in such diverse diseases like IgA nephropathy, lupus nephritis, 
membranoproliferative glomerulonephritis and diabetic nephropathy (Bohle et al., 1976) – 
each of them with a high risk to progress to glomerulosclerosis – the irreversible end stage of 
inflammatory kidney diseases with glomerular scarring and subsequent loss of function 
(Pesce et al., 1991; Floege et al, 1992). MC proliferation inhibitors like heparin, neutralizing 
antibodies to PDGF, angiotensin converting enzyme (ACE) inhibitors and others could reduce 
ECM accumulation and sclerotic changes in animal models (Kurogi, 2003), which 
emphasizes the critical role of MC proliferation in glomerulopathy.  
On the other hand in some glomerular diseases like human poststreptococcal 
glomerulonephritis or certain types of lupus nephritis, MC proliferation is part of a controlled 
repair process, in which the transient increase of MC is followed by MC loss and I - Introduction                                                                                                                            - 2 - 
reconstitution of the glomerulus (Haas et al., 1999). A well characterized experimental model 
of a mesangioproliferative disease is the anti-Thy 1.1 GN in rats. The Thy-1.1 antigen is 
located on the cell surface of MC (Paul et al, 1984). Injection of complement activating 
antibodies against the Thy-1.1 antigen leads to an initial injury with up to 90 % loss of MC, 
which is followed by a mesangioproliferative phase with ECM accumulation and finally 
resolution with return to almost normal histology after several weeks (Bagchus et al., 1986; 
Ishizaki et al., 1986).  
One way to attain the loss of MC is apoptosis. Apoptosis or the programmed cell death is 
regarded as the major mechanism to counteract mesangial hyperplasia (Baker et al., 1994; 
Shimizu et al., 1995). And it is indeed an effective weapon to oppose hypercellularity, but it is 
also responsible for incomplete cell repopulation and bares the risk of insufficient repair. 
Apoptotic cells are found in late stages of glomerulosclerosis - associated with glomerular cell 
deletion and abnormal ECM accumulation (Sugiyama et al., 1996).  
Reactive oxygen species (ROS) and nitric oxide (NO) – both produced in the course of GN - 
are known mediators of programmed cell death. (Brüne et al., 1998). NO, a diffusible gas 
with various physiological and pathological properties, is synthesized by three forms of nitric 
oxide synthases (NOS) by the oxidation of L-arginine to citrulline and NO. Besides its 
apoptotic and cytotoxic features, it exerts many additional effects including stimulation of 
proliferation, cell-protection and regulation of gene-expression just to name some of them 
(Beck et al., 1999). In anti-Thy-1.1 GN there is a massive infiltration of neutrophils and 
macrophages into the glomerulus. Macrophages represent the majority of iNOS positive cells 
within the first 24 h after anti-Thy.1.1-injection (Yamamoto and Wilson, 1987). Inhibition of 
NO production by the arginine analogue L-NMMA results in almost complete abrogation of 
mesangiolysis (up to 90%), whereas addition of L-arginine – the substrate for NO generation - 
aggravates mesangiolysis (Narita et al., 1995). This accentuates the predominant role of NO 
as a central trigger to MC death. In the last decades a series of mediators of MC proliferation 
have been characterized. This includes autacoids, growth factors, hormones and cytokines that 
have been examined by in vivo and in vitro studies. In anti-Thy-1.1 GN MC proliferation is 
mediated primarily by platelets (Johnson et al., 1991) and the release of preformed bFGF 
from injured MC. Platelets are a rich source of promitogenic factors including platelet-derived 
growth factor (PDGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), 
insulin-like growth factor I (IGF-1), extracellular nucleotides and vascular epithelial growth 
factor (VEGF), which are released upon activation. (Jefferson and Johnson, 1999).  I - Introduction                                                                                                                            - 3 - 
Among these factors the most prominent and potent mitogen for MC proliferation is platelet 
derived growth factor (Abboud 1995; Heldin and Westermark 1999, ). This soluble mediator 
exists in five different isoforms and is able to increase the thymidine incorporation rate of MC 
up to 15-fold depending on the isoform supplied. PDGF, which is also synthesized by MC 
induces its own mRNA expression, thus providing the basis for an autocrine growth 
mechanism. Under physiological circumstances glomerular PDGF synthesis and particularly 
PDGF receptor expression is low (Pfeilschifter and Hosang, 1991) but both parameters 
increase in experimental and human mesangioproliferative diseases (Abboud, 1993; Johnson 
et al., 1993).  
It is worth mentioning that during glomerular injury counteracting mediators tackle 
glomerular cells: on the one hand NO, a potent inducer of MC death and on the other hand 
PDGF, the most potent effector of MC proliferation. Both, NO and PDGF are highly 
produced in inflammatory kidney diseases and exert partially cooperative and partially 
antagonising effects. A closure look to the regulatory interactions between NO and PDGF 
may help to understand the contradictory reports on NO under inflammatory conditions. In 
1991, Pfeilschifter first reported that PDGF inhibits dose-dependently cytokine-induced NO-
synthase activity in MC. My thesis particularly addresses the reciprocal control mechanisms 
of NO on the PDGF signalling system in glomerular MC.  
 
1.2 Platelet-derived growth factor  
Growth factors are polypeptides that serve as soluble intercellular signalling molecules. The 
ligation of the membrane-bound growth factor receptors activates intracellular signalling 
cascades resulting in proliferation, migration or differentiation of the target cells.  
Platelet-derived growth factor (PDGF) is one of the most prominent representatives of the 
growth factor family with a tremendous mitogenic activity on mesenchymal cells including 
MC, fibroblasts, smooth muscle cells and other (Heldin et al., 1996, Raines et al., 1990). 
 
1.2.1 Structure of PDGF 
PDGF was originally isolated from the α-granules of human platelets (Antoniades et al.,1979; 
Heldin et al., 1979; Raines and Ross 1982) but have since been found in many normal as well 
as transformed cell types (Raines et al., 1990). It is an approximately 30 kDa cationic homo- 
or heterodimer, which consist of two disulfide-bonded polypeptides, termed A- (17 kDa) and 
B-chain (14 kDa). The combination of these two chains leads to the three well known 
isoforms PDGF-AA, PDGF-BB and PDGF-AB. The mature parts of PDGF-A- and B-chains I - Introduction                                                                                                                            - 4 - 
are approximately 100 amino acid residues long and show 60% amino acid sequence identity. 
Both chains are synthesized as precursor molecules and reveal the twofold molecular weight 
of the mature protein chain (Östman et al., 1991). 
70% of the PDGF source in human thrombocytes is composed of PDGF-AB, 5-25 % of 
PDGF-BB and the rest of PDGF-AA (Hammacher et al., 1988; Raines et al., 1990). 
In recent years two new members of PDGF-family were identified PDGF-CC (Li et al., 2000) 
and PDGF-DD (Bergsten et al., 2001; LaRochelle et al., 2001). The C- and D-chain do not 
combine for heterodimers.  
 
1.2.2 Expression and regulation of PDGF 
Positive regulators of PDGF production in MC are growth factors (PDGF, EGF, FGF, TGF-β, 
TGF-β, TNF), vasoactive compounds (angiotensin II, endothelin, thrombin), phospholipids, 
(phosphatidic acid, phosphatidylserine), lipoproteins (LDL, VLDL) and PKC agonists 
(Betsholtz, 1993; Abboud, 1995). 
MC and other cells grown in culture secrete mainly the PDGF-AA and PDGF-AB isoforms 
and hardly PDGF-BB. One reason for the low amount of PDGF-BB-secretion is that MC 
predominantly express PDGF-A-chain mRNA and to a much lesser extent PDGF-B-chain-
mRNA. (Betsholtz et al. 1986, Abboud et al., 1987, Pfeilschifter and Hosang, 1991). 
Furthermore, the amount of active PDGF A-chain and especially B-chain can be reduced by 
interaction with extracellular matrix molecules like different types of collagens 
(Somasundaram et al., 1996), thrombospondin (Hogg et al., 1997), SPARC (secreted protein 
acidic and rich in cysteine, also known as BM-40 or osteonectin) (Raines et al., 1992) and 
soluble proteins like α2-macroglobulin (Lamarre et al., 1991).  
 
1.2.3 Platelet-derived growth factor receptors  
PDGF receptors (PDGFR) are tyrosine kinase receptors (RTK) that need to dimerize for 
activation (Heldin et al., 1989). Each subunit of the PDGF molecule binds to one receptor 
monomer. Therefore, two receptor monomers are needed to be activated by one PDGF 
isoform. Dimerization narrows the distance between the intracellular parts of the receptor 
monomers and allows for transphosphorylation of tyrosine residues through basal kinase 
activity between the two receptor subunits in the complex. There are two receptor subunits 
denoted as α-and the β-receptor with a molecular size of approx. 170 and 180 kDa, 
respectively (Heldin and Westermark, 1999).  I - Introduction                                                                                                                            - 5 - 
Membrane-bound RTK´s are composed of an extracellular, a transmembrane and an 
intracellular domain. The extracellular part of PDGF receptors consists of five 
immunoglobulin-like domains, whereby the outer three domains are responsible for ligand 
binding. The transmembrane domain is followed by a 49 amino acids long juxtamembrane 
domain which is important for binding of e.g. src kinases or adapter proteins. The adjacent 
tyrosine kinase domain is interrupted through a characteristic 100 amino acids long sequence 
without catalytic activity. Also this domain has tyrosine residues that are autophosphorylated 
during activation (Claesson-Welsh et al, 1989; Matsui et al., 1989). 
Both receptors show different binding abilities. Whereas the α-receptor only binds the B-
chain, the α-receptor is able to bind both chains. Therefore binding of PDGF-AA results in 
dimerization of αα-receptor homodimers, PDGF-AB induces αα-receptor homodimers plus 
αβ-receptor heterodimers and PDGF-BB enables the formation of all three dimeric receptor 
combinations (αα-, αβ- and ββ-receptor dimers) (Seifert et al., 1989). 
PDGF-DD is only known to bind to and to form PDGF receptor ββ complexes (Bergsten et 
al., 2001; LaRochelle et al., 2001), whereas PDGF-CC – similar to PDGF-AB - is able to 
induce dimerization of PDGFR-αα and PDGFR-αβ-complexes (Gilbertson et al., 2001).  
Dimerization of different receptor combinations exert similar but not identical cell responses.  
These cell responses depend on the cell type and the amount of receptor present (Heldin and 
Westermark, 1999). 
 
1.2.4 Regulation of PDGF receptor expression 
The amount of receptor is not constant and can be increased during inflammation) and after 
hormone or cytokine treatment (Rubin et al., 1988. The regulation of the two subunits is 
mediated differentially and regulatory elements evoke diverse response patterns in distinct 
cell types and species. (Fukuoka et al., 1998; Xie et al., 1994). 
The promoter of the α-receptor in human, rat or other species has been isolated (Wang and 
Stilles, 1994) and the molecular mechanisms of PDGFR-α gene transcription have been 
extensively studied. Kitami et al. (1995) found out that the promoter region between 
nucleotides –246 and –139 is responsible for the upregulation of PDGFR-α in hypertrophic 
vascular smooth muscle cells of genetically hypertensive rats. This domain includes an 
enhancer core sequence, which specifically interacts with CCAAT/enhancer binding protein 
(C/EBP) δ (Kitami et al., 1995; 1999; Fukuoko, 1999). C/EBP-δ is a member of the basic 
leucine zipper transcription factor family and is highly upregulated in inflammatory 
conditions and specifically in response to IL-1β and cAMP stimulation (Eberhardt et al., I - Introduction                                                                                                                            - 6 - 
2000). However, soluble factors are not the only regulatory elements for PDGFR expression. 
Barrett et al. (1996) showed that cell context is even more effective to enhance PDGFR 
mRNA and protein-levels than cytokine treatment. By varying cell density, cell attachment 
and other culture conditions in in vitro studies of human fibroblasts, they observed an increase 
of both receptor subtypes up to 50-fold. Also cell culture in three-dimensional collagen gels 
upregulated the PDGFR expression. But the results are cell-specific. Rat MC even diminish 
their PDGFR-β expression, when cultured in three-dimensional collagen gels in comparison 
to ordinary monolayer cultures on plastic (Marx et al., 1993, 1994). 
Nevertheless in cell culture conditions the expression of both receptor subunits is elevated 
when compared to in vivo models (Terracio et al., 1988), indicating that the PDGFRs are 
subjected to down-regulation by not yet characterized circumstances under physiological 
conditions in vivo.  
 
1.2.5 Dimerization and autophosphorylation of the PDGF-Receptor 
Binding of the ligand results in non-covalent dimerization of two receptor monomers, which 
leads to cross-phosphorylation of conserved tyrosine residues inside and outside the kinase 
domain. Phosphorylation of the latter sites enables downstream signal transduction molecules 
like STATs (signal transducers and activator of transcription), adaptor proteins and enzymes 
that contain SH2 domains to interact with PDGFRs (Heldin et al., 1998; Heldin and 
Westermark 1999).  
 
1.2.5.1 STAT molecules that bind to PDGFR 
STATs are cytosolic transcription factors that are important downstream effector molecules of 
interferon and other cytokine receptors. After interferon or cytokine treatment members of the 
Janus kinase family (Jaks) of cytoplasmic tyrosine kinases (Tyks) are activated and 
subsequently phosphorylate STAT proteins. The STATs can then dimerize with one another 
on their SH2 domain and the new formed homo- or heterodimers translocate to the nucleus 
and initiate transcription of target genes (Darnell, 1997). PDGFR can activate STATs 
indirectly through activation of Jaks (Vignais et al., 1996) or directly via binding of STATs to 
the receptor (Ghosh -Choudhury et al., 1998). 
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1.2.5.2 Enzymes and adapter proteins that bind to the PDGF receptors  
Many enzymes associate with PDGFRs either directly or via SH-2 domains-containing 
adapter proteins like Shc, Nck, Grb7, Grb10, Grb14 or Crk, which are devoid of catalytic 
activity (Heldin and Westermark, 1999).  
The most important effector molecule of PDGF-induced signal transduction in glomerular 
MC is probably phosphatidylinositol-3-kinase (PI3-K), since inhibition of PI3-K in human 
MC dose-dependently reduced PDGF-mediated DNA synthesis and migration to basal level 
(Ghosh-Choudhury, 1997). 
PI3-K belongs to the family of enzymes that phosphorylate the inositol ring of 
phosphoinositides generating phosphatidylinositol phosphates. It consists of a p85 regulatory 
subunit and a p110 catalytic subunit. Binding of the regulatory subunit p85 with one of its 
SH2 domains to PDGFR-α or -β leads to a conformational change with subsequent activation 
of the enzyme (Panayotou et al., 1992). Activated PI3-K or its downstream effector substrates 
phosphorylate several other signal transducers that initiate diverse biological responses like 
proliferation (coactivation of PLCγ), inhibition of apoptosis (via activation of Akt/PKB) and 
cytoskeletal reorganisation with cellular migration (Kauffmann-Zeh et al., 1997; 
Vanhaesebroeck et al., 1997).  
Once bond, the appropriate PDGF dimer leads to internalization of the ligand-receptor 
complex. The complex then dissociates and the receptor is either degraded or - to a much 
lesser extent -returns back to the cell membrane (Heldin and Westermark 1999).  
 
1.2.6 Mesangial cell responses to the different PDGF isoforms 
As indicated, a number of signal transduction pathways are activated through PDGFR 
dimerization. Some of these cascades overlap or differ from cell type to cell type, which 
complicates our understanding of the functions of PDGFR activation (Heldin and Westermark 
1999). 
In MC PDGF is able to stimulate proliferation, chemotaxis, contraction and its own 
expressional induction in an isoform-specific manner. The particular response may depend on 
the amount of receptors present on the cell surface.  
Cultured human MC have about ten times more binding sites for PDGF-BB than for PDGF-
AA. Abboud et al., (1994) counted 90000 binding sites for PDGF-BB, 30000 for PDGF-AB 
and 10000 for PDGF-AA. 
The discrepancy between the amount of binding sites for PDGF-AA and PDGF-AB is not 
fully clarified, whereas some authors claim (low-affinity) formation of ßß- homodimers in I - Introduction                                                                                                                            - 8 - 
response to PDGF-AB treatment (Seifert et al., 1993) others deny the ability of PDGF-AB to 
dimerize  ββ-receptors (Hammacher et al., 1989). However, about 100-fold larger 
concentrations of PDGF-AB are needed to evoke a slight mitogenic response in cells from 
patch-mice which have the α-receptor gene deleted (Seifert et al., 1993), so that the formation 
of PDGFR-ββ in response to PDGF-AB in vivo is neglectable.  
Abboud et al. (1994) further demonstrated that PDGF-AA, which is a potent mitogen in Swiss 
3T3 cells (a cell-type that expresses both receptors in similar amounts) failed to induce DNA 
synthesis and migration in cultured human MC, whereas PDGF-BB dose-dependently 
increased both parameters. One reason for the lack of mitogenic capacity of PDGF-AA, is the 
firm downregulation of the α-receptor due to constitutive secretion of PDGF-AA, and 
represents a mechanism to prevent autocrine growth. Inhibition of this endogenous PDGF 
secretion leads to a modest but significant increase of DNA-synthesis in response to 
exogenously applied PDGF-AA, giving rise to the theory that the amount of receptors dictates 
the particular effect (Abboud et al., 1994). 
PDGF-AB, which has only one third of the binding sites of PDGF-BB exerts 75% of PDGF-
BB induced mitogenic and chemotactic activity in human MC (Abboud et al., 1994; Ghosh-
Choudhurry, et al. 2000). This has lead to the assumption that the formation of αβ-
heterodimers might be even more potent than the ββ-homodimers. Cells which express equal 
numbers of α- and β-receptors give stronger responses to PDGF-AB treatment than to the 
homodimeric isoforms (Rupp et al., 1994; Heidaran et al., 1991). One reason for this 
observation is that autophosphorylation takes place at different sites in the hetero- as 
compared to the homodimer. Tyr-771 for example, a tyrosine residue that is able to bind and 
activate the ras inhibitor GAP, was found to be phosphorylated to a much greater extent in the 
homodimeric  β-complex when compared to the heterodimeric complex. Therefore, the 
heterodimeric receptor promotes less negative regulatory mechanisms than the homodimeric 
receptor complex (Heldin and Westermark, 1999, Ekman et al., 1999). 
 
1.2.7 Physiological and pathophysiological roles of PDGF  
The role of PDGF begins with embryonic development. Knock-out studies in mice revealed 
the significance for both chains (A and B-chain) and both receptors, since deletion of each of 
these components was lethal. (Betsholtz et al., 2001). 
Mice died during embryogenesis or perinatally. The phenotypes of PDGF-B chain or 
PDGFR-β knockout mice are very similar and start about embryonic day 16 (Levéen et al., 
1994; Soriano, 1994). In both cases defective formation of the vascular system is I - Introduction                                                                                                                            - 9 - 
predominant. The failure of newly formed blood vessels to recruit vascular smooth muscle 
cells (VSMC) and pericytes leads to capillary dilatation with microaneurysms, placenta 
defects, general oedema, haemorrhage and abnormal renal glomeruli, with a total lack of MC. 
PDGF-B-chain or β-R deficient mice die just before birth due to these cardiovascular 
complications (Betsholtz et al., 2001). 
The consequence of PDGF-A chain or PDGFR-α gene deletion is associated with different 
phenotypes (Boström et al., 1996; Soriano, 1997). Whereas the α-R knockouts die between 
embryonic day 8 to 10, a certain part of PDGF-A chain-deleted mice may survive up to six 
weeks after birth. However the majority dies either in embryonic stages or directly after birth 
due to respiratory insufficiency and a lack of alveolar myofibroblast. The malformations 
associated with the α-R knockouts are nevertheless more severe and include defects that are 
not seen in the PDGF-A
-/- mice, like for example spina bifida, cleft face and skeletal 
abnormalities. Even PDGF-A
 and PDGF-B
 double knockout-mice are not able to imitate the 
consequences of PDGFR-α gene disruption. This emphasizes the role of other ligands activate 
the α-R. PDGF-C is such a supposed candidate, but future experiments have to verify this 
suggestion (Betsholtz et al., 2001). 
Postnatally PDGF plays a major role in wound healing. The proliferative effects of PDGF and 
promising effects seen in PDGF-treated animal wound healing models led to the development 
of the drug Becaplermin, which is a recombinant PDGF-BB gel (Steed et al., 1995). 
Becaplermin enhances wound healing of human diabetic neuropathic ulcers slightly but 
significantly. However, despite its positive modulatory contribution to the wound-healing 
process, it did not fulfil the great expectations laid on its clinical efficacy.  
 
1.2.8 Role of PDGF in glomerulonephritis  
PDGF has the potency to mediate many symptoms that are associated with renal 
inflammation. It is an effective vasoconstrictor due to its mobilization of intracellular Ca
2+ 
and contributes to the diminished GFR in renal diseases (Abboud et al., 1993). 
Furthermore, it leads to hypercellularity of MC and subsequently to an increased deposition of 
extracellular matrix. Thereby, PDGF acts either directly or via the induction of other growth 
factors and cytokines like TGF-β (Abboud et al., 1993). These intraglomerular alterations 
may cause chronification of the disease process and finally result in glomerulosclerosis. 
In experimental and human glomerulonephritis a remarkable upregulation of PDGF and its 
receptors has been observed. Matsuda et al. (1995) studied the expression of PDGF-B and 
PDGFR-β in various forms of GN and noticed that the PDGF-B chain or the PDGFR-β were I - Introduction                                                                                                                            - 10 - 
hardly detected in normal glomeruli or minimal change nephropathy but were highly up 
regulated in mesangioproliferative forms of GN as is in Ig-A nephropathy, Henoch-Schönlein 
purpura nephritis and lupus nephritis. The amount of PDGF or its receptors correlated with 
the severity of the disease (Matsuda et al., 1995). Gesualdo et al. (1991, 1994) who made 
similar observations could furthermore, detect a slight upregulation of the PDGFR-α, 
indicating that both PDGFRs play a critical role in proliferative glomerulonephritis. 
The expression pattern of PDGFR in these studies correlated somehow with that of iNOS in 
the studies of Furusu et al. (1998). Both proteins are highly upregulated in human 
mesangioproliferative forms of GN like IgA nephropathy and lupus nephritis and are more or 
less absent in minimal change nephropathy. In both studies there was an association between 
the severity of the disease and the amount of iNOS or PDGFR expression, respectively, which 
encouraged us to analyse the interaction between NO and PDGF/R expression and function . 
 
1.3 Nitric Oxide - the discovery of an universal intercellular messenger 
A beneficial effect of diluted nitro-glycerine on angina pectoris was already claimed by 
William Murrell from London’s Westminster Hospital in 1879. But it took another 100 years 
until NO liberated by nitro-glycerine was identified as the mediator of smooth muscle 
relaxation (Palmer et al., 1987; Ignarro et al, 1987). 
In 1977, Murad could demonstrate that exogenous applied NO relaxes smooth muscle cells 
via activation of guanylate cyclase (Arnold et al., 1977). Ignarro confirmed the NO effect two 
years later and furthermore showed that NO mediates a relaxation of isolated blood vessels 
(Gruetter et al., 1979).  
In 1980, Furchgott, who was actually investigating the intracellular pathway of acetylcholine 
signalling, which led to dilatation of blood vessels in animal models, found out that 
acetylcholine does not work directly on vascular smooth muscle cells for relaxation, but via a 
substance produced by endothelial cells in response to acetylcholine stimulation (Furchgott 
and Zawadzki, 1980). He called this relaxing substance, which he was not yet able to identify, 
endothelial-derived relaxing factor (EDRF) and was now engaged to decode this unknown 
and very unstable molecule. It took several years until Salvador Moncada and Louis Ignarro 
sovereignly could verify the suspicion that EDRF and NO are one and the same molecule 
(Ignarro et al. 1987, Palmer et al, 1987).  
It was rather surprising that NO, a well known atmospheric air pollutant (Schwartz et al., 
1983) with its various toxic metabolites, would play a key role in the regulation of vascular 
tone. NO with its various biological activities was chosen as the “Molecule of the year” by the I - Introduction                                                                                                                            - 11 - 
magazine Science in 1992. And in 1998 three pioneers of NO research Furchgott, Ignarro and 
Murad were honoured with the Nobel Prize of Physiology and Medicine for their discovery of 
NO. 
 
1.3.1 Physiological role of Nitric Oxide  
NOS exists in at least three distinct isoforms: Two of them namely the endothelial and the 
neuronal forms (eNOS, nNOS, respectively) are constitutively expressed and the third form 
represents a cytokine-and endotoxin-inducible variant (iNOS). Endothelial NOS-derived NO 
plays an important role in the cardiovascular system (Marsh and Marsh, 2000). NO leads to 
relaxation of vascular smooth muscle cells via activation of the soluble guanylyl cyclase. 
Pathological conditions like arteriosclerosis disturb this highly balanced system. A subsequent 
reduced NO release is accompanied by enhanced vasoconstriction and may lead to 
cardiovascular diseases such as hypertension or angina pectoris (Shimokawa, 1999). Several 
NO releasing compounds have been developed to mimic the vasorelaxing effect of NO and to 
substitute for the lack of sufficient endogenous NO formation  (Napoli and Ignarro, 2003). 
NO is also involved in many other physiological procedures. Neuronal NOS-derived NO 
functions as a neurotransmitter in the central and peripheral nervous system (Crossin, 1991), 
whereas inducible NOS-derived NO participates in host defence (Nathan et al, 1991). 
However, in particular the latter type of NOS has been associated with diverse inflammatory 
diseases such as rheumatoid arthritis (Stichtenoth and Fröhlich, 1998), multiple sclerosis 
(Parkinson et al., 1997) and glomerulonephritis (Beck et al., 1999). Therefore NO research 
still is in motion and the list of its features grows continuously. 
 
1.3.2 Biochemistry of Nitric Oxide 
NO is a very unstable gas. The substrate for NO-generation is the amino acid L-arginine. 
Nitric oxide synthase (NOS) is the enzyme which catalyses the oxygen- and NADPH- 
dependent oxidation of a guanidino nitrogen on L-arginine to citrulline and NO.  
Cofactors for the reaction are FMN, FAD, tetrahydrobiopterin, heme, Ca
2+/calmodulin and 
possibly Zn
2+-ions (Moncada et al. 1991; Stuehr, 1999). 
NO reacts in biological systems with molecular oxygen (O2) or other nitrogen species, 
superoxide (O2
-), transition metals (M) and thiol group-containing proteins - forming products 
such as higher nitrogen oxides (NOx; N2Ox), peroxynitrite (OONO
-), metal nitrosyl adducts 
l(M-NO) and S-nitroso compounds. The metabolites of NO themselves undergo diverse I - Introduction                                                                                                                            - 12 - 
chemical reactions which may contribute to normal biological activity but also to cytotoxity 
(Stamler et al., 1992,1994 ). 
One reason for the versatility of NO is the great capacity of nitrogen to form compounds in all 
oxidation states ranging from –3 to +5. The NO molecule contains nitrogen in the +2 
oxidation state and consequently an unpaired electron in its valence shell. This unpaired 
electron facilitates both - reduction (forming NO
-, nitroxyl anion) and oxidation (forming 
NO
+, nitrosonium ion) of NO. NO
- and NO
+ have their own chemical properties like higher 
affinity to thiol groups which again enhances the multifarious reaction of NO (Wink et al., 
1994).  
 
1.3.3 Regulation of Nitric Oxide Synthases 
The main difference between the constitutive isoforms and iNOS concerns the regulation of 
activity: Both constitutively expressed isoforms need Ca
2+ calmodulin for activation. Their 
activation state depends on changes of intracellular free Ca
2+ concentration. By contrast the 
inducible NOS already contains Ca
2+ calmodulin bound to the enzyme and does not require an 
elevation of intracellular Ca
2+-level for activation (Cho et al., 1992).In general, the activity of 
iNOS depends on the amount of newly synthesized protein. The expression is induced by 
different inflammatory stimuli such as TNF-α, LPS, IFN-γ, IL-1βcAMP on the transcriptional 
level, but the response is highly cell- and species-specific (Beck et al., 1999).  
Expression of the protein is increased after interaction of certain transcription factors with the 
iNOS promoter. In rat MC two very potent inductors for iNOS expression are cAMP and IL-
1β (Kunz et al., 1994, Mühl et al., 1994).  
Cyclic AMP induces the transcription factor CAAT/enhancer-binding protein (C/EBP), which 
binds and activates the iNOS promoter (Eberhardt et al., 1998). IL-1β acts via induction of 
nuclear factor κB (NF-κB) that activates the iNOS promoter as well (Eberhardt et al., 1994, 
1998). Nevertheless, the vasopressor endothelin-1 is able to inhibit cytokine-induced iNOS 
expression without influencing NF-κB (Beck and Sterzel, 1996) indicating that further 
mechanisms contribute to cytokine-induced iNOS expression. Once expressed iNOS is active 
for hours to days and produces NO in much higher quantities than the constitutive isoforms 
eNOS and nNOS.  
The effects of NO are diverse and depend on the amount of NO formed as well as the 
susceptibility of the target cell to NO. At low concentrations NO stimulates guanylyl cyclase 
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messenger molecule which regulates for example vascular homeostasis (Arnold et al., 1977; 
Katsuki et al., 1977). 
Higher concentrations of NO produced by iNOS interact with thiol groups and transition 
metal-containing proteins and can alter protein function or gene expression. At high 
concentrations NO leads to cell damage, apoptosis and even necrosis – giving macrophages 
an effective weapon against infected cells and harmful micro-organisms. But also healthy 
cells can be destroyed. In particular, during inflammatory processes, that are often associated 
with pathologically high NO concentrations, the NO effect is mainly deleterious. The 
inhibition of iNOS in appropriate inflammatory animal models has been shown to exert 
beneficial effects. Therefore, it is of great interest to identify substances that inhibit cytokine-
induced iNOS expression at the transcriptional level without affecting the constitutive 
isoforms eNOS or nNOS (Pfeilschifter et al., 1996, Beck et al., 1999) to avoid an imbalance 
of the physiological and beneficial effects of NO.  
 
1.3.4 Signalling pathways and effects of Nitric Oxide  
NO mediates its action by diverse mechanisms. The main signalling pathways leading to cell 
responses are initiated directly by interactions with certain enzymes, transcription factors and 
DNA or indirectly via activation of guanylyl cyclase and formation of cGMP (Beck et al., 
1999). 
 
1.3.4.1 Nitric Oxide and soluble guanylyl cyclase (sGC) 
Exogenously applied or endogenously produced NO interacts with the heme moiety of soluble 
guanylyl cyclase (Ignarro, 1990) to form a ferrous-nitrosyl-heme-complex. This complex 
leads to a 200-fold induction of the enzyme activity, which catalyses the biosynthesis of 
cyclic 3´,5´-guanosine monophosphate (cGMP) from guanosine triphosphate. 
The increase of the cGMP level modifies the activity of three main class of target proteins 
(Schmidt et al., 1993): cGMP-dependent protein kinases (PKG, responsible for the dilatative 
effect of NO in VSMC), cGMP-regulated phosphodiesterases (PDE, enzymes that modulate 
intracellular cyclic nucleotide concentrations) and cGMP-regulated ion channels, which play a 
major role in the sensory system (Dhallan et al., 1992; Breer and Shephard, 1993).  
 
1.3.4.2 Nitric Oxide and gene expression 
NO alters the expression of diverse genes by modulation of mainly redox-sensitive 
transcription factors like NF-κB or activator protein-1 (AP-1) (Sen and Packer, 1996; I - Introduction                                                                                                                            - 14 - 
Pfeilschifter et al., 2001). Furthermore, it influences mRNA stability (Beck et al. 1999, Akool 
et al., 2003) and evokes posttranslational modifications Vodovotz et al., 1999; Bogdan, 2001; 
Franzen et al., 2002).  
NF-κB is a homo- or heterodimeric transcription factor (consisting of p50/p50; p65/p65; 
p50/p65-dimers). In its inactive status it is bound to members of the IκB family of inhibitory 
proteins in the cytosol. It participates in immunological events and therefore is predominantly 
present in macrophages and lymphocytes. Activation of these cells by cytokines or oxygen 
radicals such as O2
-
 or H2O2  results in activation of an IκB-kinase (IKK) which leads to 
phosphorylation, ubiquitination and degradation of IκB. Subsequently NF-κB is liberated, and 
then can enter the nucleus to initiate transcription of numerous target genes (Stancovski and 
Baltimore, 1997) like iNOS (Eberhardt et al., 1994; 1998).  
NO, with both anti-oxidant and pro-oxidant properties can either stimulate (Lander et al., 
1993; von Knethen et al., 1999) or inhibit (Peng et al., 1995) NF-κB activity depending on the 
cell-type and concentration of potential reaction partners such as superoxide and hydrogen 
peroxide or other reactive oxygen species (Beck et al., 1999). NO-mediated induction of NF-
κB is comparable to the mechanisms of ROS: IKK is activated either directly or via the 
Ras/Raf cascade, resulting in depletion of NF-κB-inhibitor IκB (Lander et al., 1995;1996).  
Whereas inhibition of NF-κB activity is attained via scavenging of O2
-
 and thus reduction of  
H2O2 formation with the consequence of reduced IKK activation and reduced NF-κB 
liberation as shown for macrophage colony stimulating factor (Peng et al., 1995) and for 
monocyte chemoattractant protein 1 (Beck et al., 1999).  
Furthermore, in vitro studies revealed that NO is able to inhibit NF-κB activity through direct 
S-nitrosation of a crucial cysteine residue on its DNA-binding domain, thus hindering NF-κB 
to contact its cognate DNA-binding site (Matthews et al., 1996).  
A direct inhibitory effect by nitrosation of critical cysteines in the DNA-binding domain has 
also been shown in vitro for the transcription factor AP-1 (Nikitovic et al., 1998). AP-1 is a 
heterodimer that belongs to the basic domain leucine zipper family consisting of the two 
proto-oncogene products c-Fos and c-Jun. c-Fos and Jun B gene expression can be induced by 
NO through upstream regulatory events like activation of cGMP-dependent protein kinases 
(Haby et al., 1994; Pilz et al., 1995). AP-1 binds to phorbol ester responsive elements (TRE), 
which can be found in the promoter regions of many genes (Beck et al., 1999)  
NO furthermore inhibits gene transcription via activation of a DNA methyltransferase 
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CpG islands and impedes further binding of transcription factors on the gene promoter 
(Hmadacha, et al., 1999). 
NO can also exert posttranscriptional effects on gene expression. Recently, Eberhardt et al. 
(2002) observed a NO-dependent downregulation of the matrix metalloproteinase-9 gene. 
Analysis of mRNA stability revealed an effect of NO on the MMP-9 mRNA turnover in MC. 
Moreover this decrease in mRNA stability is due to an attenuated expression of the ELAV 
protein HuR (Akool et al., 2003). 
NO exerts to posttranslational modifications of proteins like transforming growth factor-α. 
NO attenuates the expression of TGF-β mRNA (Craven et al., 1997) but initiates positive 
posttranslational alterations of the molecule (Bogdan, 2001; Vodovotz et al., 1999). The 
amount of active TGF-β is therefore enhanced and leads for example to inhibition of iNOS 
expression. Furthermore,  Franzen et al.  (2002) reported an enhanced degradation of the 
neutral ceramidase by NO. 
The fact that NO affects expression of protective and deleterious gene products complicates 
the pharmacological establishment of NOS inhibitors in the treatment of inflammatory 
diseases. For example, NO has beneficial properties as it inhibits extracellular matrix proteins 
like collagen I (Chatziantoniou et al., 1998) and mitogenic growth factors like vascular 
endothelial growth factor (VEGF) in VSMC (Tsurumi et al., 1997; Liu et al., 1998). But it 
also contributes to aggravation of inflammatory diseases since NO induces several potent 
proinflammatory cytokines like TNF-α (Zhang et al., 2000) and IL-8 (Villarette and Remick, 
1995). Possibly the most challenging feature in NO-mediated gene regulation is the induction 
of its own biosynthesis. The subsequent excessive high NO formation may trigger apoptotic 
or even necrotic cell death with partially irreversible damage of the involved tissue (Mühl and 
Pfeilschifter, 1995). 
 
1.3.5 Nitric oxide and apoptosis 
Apoptosis – the programmed cell death - follows an universal pattern characterized by 
chromatin condensation, DNA cleavage, cell shrinkage, membrane blebbing and 
redistribution of phosphatidylserine from the inner to the outer leaflet of the cell membrane 
(Kerr et al., 1972). The major part of these morphological changes is caused by proteases of 
the caspase family (Alnemri et al., 1996).  
These cysteine proteases stay at critical decision points of the apoptotic pathway and cleave 
distinct cellular proteins such as the poly(ADP-ribose)polymerase (PARP), nuclear lamin, 
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residues, which can result either in the loss of function or in an activation of the target protein. 
There are two main pathways for apoptosis, namely the extrinsic and the intrinsic pathway. 
Both pathways direct to induction of the downstream effector caspase, caspase-3 (Hengartner, 
2000; Reed, 2000). 
In the extrinsic pathway activation of caspase-8 results after ligation of the appropriate ligand 
on the extracellular domain of the TNFR or FasR (Salvesen and Dixit, 1997). In the intrinsic 
or mitochondrial pathway, proapoptotic substances that are stored between the outer and the 
inner mitochondrial membrane like cytochrome c (activator of caspase-9) are released after 
changes in the homeostasis of Bcl-2 family members (Reed, 1997a).  
Bcl-2 family proteins could principally divided into two groups: the anti-apoptotic members 
(e.g. Bcl-2, Bcl-XL, Mcl-1) that stabilize the mitochondrial membrane potential and the pro-
apoptotic members (e.g. Bax, Bad, Bim), that facilitate the discharge of the pro-apoptotic 
substances stored in the mitochondria (Reed, 1997b, 1998) .  
NO shifts the balance between the two groups through induction of the tumour suppressor p53 
towards apoptosis. Normally the amount of p53 is low, but hypoxia or high amounts of NO 
lead to stabilization of the protein and therefore initiation of apoptosis (Meßmer et al., 1994; 
Meßmer and Brüne, 1996).The activity of Bcl-2, which is a potent antiapoptotic protein 
(Meßmer et al., 1996a,b) can subsequently be inhibited by the nuclear phosphoprotein p53 by 
upregulation of its inhibitor Bax, (Bcl-2 associated protein x) which binds to and antagonizes 
Bcl-2. High amounts of NO or hypoxia further lead to nitrosative or oxidative DNA damage – 
another mechanism for p53 accumulation. 
There are also p53 independent mechanisms described that lead to NO-induced apoptosis. NO 
affects the mitochondrial membrane directly - leading to cytochrome c release and inhibition 
of mitochondrial respiration (Meßmer and Brüne, 1996; Kim et al., 2001). 
Furthermore, NO activates cJun N-terminal kinases1and 2 (JNK1/2). JNK- or stress activated 
protein kinases are known inducers of apoptosis(Xia et al., 1995; Pfeilschifter and Huwiler, 
1996), which evoke accumulation of caspase 3.  
During or prior the initiation of apoptosis also antiapoptotic proteins can be activated. 
Induction of antiapoptotic proteins explains at least partly the contradictory observations in 
NO-mediated cell death: 
MC and RAW 264.7 macrophages respond to different NO donors time- and concentration-
dependently with apoptosis (Brüne et al., 1998, Beck et al, 1999). While macrophages also 
die in response to endogenous NO production, MC stay resistant to cytokine mediated NO 
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apoptosis protein family (IAP) are downregulated in macrophages, while constant IAP protein 
levels can be measured in MC after cytokine treatment (Manderscheid et al., 2001). Another 
reason for this cell-type specific behaviour is the simultaneous generation of O2
-. Cytokine 
treatment stimulates not only iNOS, but also NAD(P)H oxidases – the main producers of 
ROS in MC. O2
-, which is on its own a potent proapoptotic substance in MC, reacts with NO 
and detoxifies it by forming peroxynitrite (ONOO
-) (Sandau et al., 1997). In most cell-lines 
the potent oxidant peroxynitrite mediates highly cytotoxic effects. Its protective role against 
NO plus ROS induced apoptosis in MC is due to the presence of reduced glutathione (GSH), 
an antioxidant that reacts rather with peroxynitrite and allows MC to cope with their toxic 
compound. Depletion of reduced GSH in MC induces apoptosis in the presence of both 
metabolites (NO and O
2-) (Sandau et al., 1999). 
Also shifting the balance between NO and superoxides towards NO by additional 
supplementation of NO initiates MC death (Sandau et al., 1997).Another important method 
how cells protect themselves against NO mediated apoptosis is the generation of cytokines or 
growth factors (Mooney et al., 1997). Incubation with 10 % FCS was shown to protect MC 
completely against NO-mediated DNA fragmentation through phosphorylation of p42/44 
MAPK (Sandau et al., 1999). Therefore the cellular response to even high amounts of NO 
does not necessarily lead to apoptosis. The balance between pro- and antiapoptotic stimuli 
determines at last whether cells can protect themselves against ROS, NO or hypoxia mediated 
apoptosis or not (Pfeilschifter et al., 2001). 
 
1.3.6 Nitric Oxide and glomerulonephritis  
GN can be classified by morphological, clinical and pathogenetic aspects. Disease induction 
is mediated e.g. by antibodies or T-cells, that affect directly (autoimmune diseases) or 
indirectly (immuncomplex nephritis) glomerular structures and initiate an inflammatory 
response with complement activation and/or infiltration of immune cells like macrophages 
and neutrophils. Macrophages play a critical role in human and experimental 
glomerulonephritis. The amount of invading macrophages in human lupus nephritis correlates 
with glomerular dysfunction (Alexopoulous, 1990) and makes the progression of e.g. human 
IgA nephropathy predictable (Ootaka et al., 1995). However an universal mechanism how 
macrophages contribute to renal injury still has to be elucidated. In 1988, Hibbs et al. declared 
NO as an important effector molecule of activated macrophages, which produce iNOS derived 
NO in high quantities. The gas NO and activated macrophages were able to impair L10 
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experimental GN (Cattell et al., 1990), made NO, the precursor molecule of nitrite a potential 
candidate for macrophage-mediated cytotoxicity also in glomerulonephritis.  
But the role of NO in GN still is controversially discussed. There are studies that claim a 
beneficial effect of NO. Ferrario et al. (1994) inhibited NOS activity with the unspecific NOS 
inhibitor L-NMMA in acute nephrotoxic serum nephritis. These authors reported that 
inhibition of NOS aggravates the course of the disease. One year later, in 1995, Narita et al. 
reduced the L-NMMA-concentration and chose the anti-Thy1 nephritis as an experimental 
model. They used lower concentrations of L-NMMA to avoid severe inhibition of the 
protective eNOS in renal vessels. They observed that inhibition of iNOS reduced 
mesangiolysis up to 90 per cent – which underlines the harmful, destructive role of iNOS-
derived NO in GN. eNOS-derived NO on the other hand exert beneficial effects as it 
decreases blood pressure, and inhibits platelet adhesion and aggregation (Radomski et al., 
1993). The lack of eNOS in accelerated anti-glomerular basement membrane nephritis 
worsens the course of the disease with increased mortality and morbidity of eNOS knock-out 
mice (Heeringa et al., 2000). In several types of experimental and human glomerulonephritis 
(e.g. IgA nephropathy, lupus nephritis) there was a significant downregulation of eNOS 
expression. The extent of eNOS expression inversely correlated with the degree of glomerular 
injury and with iNOS expression (Furusu et al., 1998).  
One reason for the downregulation of eNOS might be the inhibitory effect of large amounts of 
NO on eNOS (Rengasamy and Johns in 1993). Griscavage et al. (1995) showed that the 
constitutive expressed nNOS and eNOS isoforms were more susceptible towards NO than 
iNOS. From a certain concentration range NO even induces iNOS expression and therefore its 
own synthesis (Mühl and Pfeilschifter, 1995). However, higher concentrations of NO may 
also impair iNOS activity. This negative-feedback-mechanism is supposed to be regulated 
through NF-κB inactivation (Connelly et al., 2001) or by direct inhibition of iNOS enzyme 
activity (Mühl and Pfeilschifter 1995). But also other negative regulatory mechanisms in the 
course of diseases like the upregulation of PDGF might be responsible for the downregulation 
of iNOS expression.  
Selective inhibition of iNOS by L-NIL (L-N6-(l-iminoethyl)lysine) in a septic shock model 
leads to a stabilisation of the GFR. Whereas nonselective NOS inhibition attenuated GFR in 
LPS treated mice (Cheng et al., 2003). These data and eNOS-gene-knockout studies (Albrecht 
et al., 2003) underline the importance of eNOS-derived NO for glomerular function in 
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The role of iNOS in inflammatory renal diseases is not that consistently characterized. Cattell 
et al. (1998) reported that iNOS knockout mice do not show differences in proteinuria or 
histology compared to wild type mice in accelerated nephrotoxic nephritis, indicating that 
iNOS-derived NO does not contribute to the course of disease. However, there are different 
types of glomerulonephritis. Furusu et al., (1998) investigated the expression and source of 
eNOS and iNOS in 4 distinctive types of human glomerulonephritis. The renal biopsies were 
taken from different patients with IgA nephropathy (IgAN), Lupus nephritis (LN), 
membranous nephropathy (MN) and minimal change nephritic syndrome (MCNS).  
In MN, MCNS and control biopsies iNOS expression was hardly detected. Whereas 
significant changes of iNOS expression were perceived in IgAN and LN. In these 
proliferative glomerulonephritis types iNOS was highly upregulated and the extent of iNOS 
expression correlated positively with the severity of the disease. Furthermore, Furusu et al. 
(1998) reported that the major part of iNOS positive cells were glomerular resident cells and 
not macrophages.  
Taken together, the role of NO in glomerulonephritis is not yet completely understood. NO 
with its diverse capacities may exert beneficial as well as harmful effects. 
 
1.4 Aim of this study: Effects of Nitric Oxide on PDGF/PDGFR activity 
Little is known about NO modulated effects on PDGF/PDGFR activity. Callsen et al. (1999) 
described that NO enhances PDGFR phosphorylation indirectly via inhibition of a tyrosine 
phosphatases. This NO modulated inhibition is due to interactions with cysteine residues in 
the active site motif of  phosphatases and is also reproduced by application of superoxides. 
Another indirect mechanism how NO affects PDGF activity is by a down-regulation of 
SPARC, which is a matrix constituent and potent scavenger of PDGF. Thus inhibition of 
SPARC expression leads to an enhanced availability of PDGF for its receptors and therefore 
increased activity (Walpen et al., 2000). 
However, no direct NO-induced alterations in PDGFR mRNA or protein levels were 
demonstrated in either of these reports. Therefore, we analysed the effects of NO on the 
expression of the PDGF receptors subtypes. This study was performed to enhance our 
knowledge in the complex crosstalk of NO generating mechanisms and the PDGF signalling 
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II - M A T E R I AL S  &  M E T H O D S 
 
 
2.1 Materials 
 
2.1.1 Apparatus 
 
Agarose Gel Electrophoresis chamber  Sub Cell GT Agarose Gel Electrophoresis 
System, Bio Rad 
Agarose Gel Dokumentation System  Gel Doc 1000, Amersham 
Autoclave Varioclave 
Autoradiography Cassettes  Amersham Pharmacia Biotech 
AutoLumat LB953  Berthold, Pforzheim 
Blotting machine (for WB)  Trans-Blot° sDCell, No. 221BR 
Centrifuge  Heraeus Megafuge 1.0, rotor 7570F Biofuge 
fresco, Heraeus instruments 
Distillator  Milli-Q Plus PF UltraPure Water System 
(Millipore Waters,Bedford, USA) 
Fuji film processor  Hyperprocessor, Amersham 
Hybridisation-oven Hereaus  Instruments 
Incubator  Heraeus BBD 6220 incubator 
Microplate Reader Benchmark  BioRad 
Microscope Aciovert  25  Zeiss 
PCR-cycler  Gene Amp PCR System 9700 PE Applied 
Biosystems 
Photometer for DNA/RNA  Gene Quant II, Amersham Pharmacia Biotech
Phosphorimager Fuji 
Reverse Transcriptase Cycler  Reverse Transcriptase Mastercycler 5330 
Semi-dry blotting apparatus  Bio-Rad, München, Germany 
Scales Sartorius  research 
Sequencer ABI-PRISM
TM Perkin Elmer 310 Genetic 
Analyzer 
Sonifier  Sonifier „W-450“ (Branson) 
Sterile bench  Heraeus, Kendro 
Thermomixer  Eppendorf Thermomixer comfort 
Heidolph Duoax 1030 
Vortexer  Vortex 2 genii scientific industries 
 
2.1.2 Chemicals 
 
Acetone Merck,  Darmstadt 
Acrylamide / bisacrylamide-solutions Roth,  Karlsruhe 
Agar  Gibco Life Technologies, Karlsruhe 
Agarose Biozym,  Oldendorf 
Ammoniumpersulfate Sigma  Aldrich Fine Chemicals, Deisenhofen II - Materials & Methods                                                                                                         - 21 -                     
Ampicillin  Sigma Aldrich Fine Chemicals, Deisenhofen 
Boric acid  Merck, Darmstadt 
Bovine serum albumin  Sigma Aldrich Fine Chemicals, Deisenhofen 
Bradford Reagent  BioRad 
8-Br-cAMP Sigma,  Deisenhofen 
Bromphenolblue Serva 
[α-
32P]CTP  Amersham Pharmacia, Freiburg 
Chloroform Merck 
DETA NONOate (1-[2-(2-Aminoethyl)-N-
(2-ammonioethyl)amino] diazen-1-ium-1,2-
diolate)  
Alexis, Läufelingen, Switzerland 
Diethylpyrocarbonate (DEPC)  Sigma Aldrich Fine Chemicals, Deisenhofen 
Diphenylamine Sigma  Aldrich  Fine Chemicals, Deisenhofen 
Dithiothreitol (DTT)  Sigma Aldrich Fine Chemicals, Deisenhofen 
DMSO Merck,  Darmstadt 
Dual-Luciferase
® Reporter Assay System  Promega, Mannheim 
ECL Detection Kit/Films  Amersham Pharmacia, Freiburg 
EDTA Sigma  Aldrich  Fine  Chemicals, Deisenhofen 
Effectene Transfection Reagent (4x 1ml)  Qiagen, Hilden 
Ethanol J.T.Baker 
Ethidium bromide  Sigma Aldrich Fine Chemicals, Deisenhofen 
EDTA Sigma  Aldrich  Fine  Chemicals, Deisenhofen 
Fetal calf serum  Gibco Life Technologies, Karlsruhe 
Formamid J.T.Baker 
Glycerol Roth,  Karlsruhe 
Glycine Merck,  Darmstadt 
HEPES Roth,  Karlsruhe 
Immobilon
TM –P Polyvinylidene Difluoride 
Transfer Membrane 
Millipore, Eschborn 
Insulin-Transferrin-Sodium Selenite 
Supplement 
Roche Biochemicals, Mannheim 
Interleukin-1β  Novartis Pharma, Basel 
Isopropylalcohol J.T.Baker 
Isopropylthiogalactopyranoside (IPTG)  Roth, Karlsruhe 
Loading Dye Solution 6x  MBI Fermentas 
Methanol J.T.  Baker 
β-Mercaptoethanol  Sigma Aldrich Fine Chemicals, Deisenhofen 
Molecular weight markers (DNA)  MBI Fermentas, St. Leon-Rot 
Molecular weight markers (protein)  Amersham Pharmacia, Braunschweig 
N
G-monomethyl-L-arginine Calbiochem, Schwalbach 
Nucleotide triphosphates  PE Biosystems, Weiterstadt 
NucleoSpin
® Extract 2 in 1  Macherey & Nagel, Düren 
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ODQ   Alexis, Grünberg 
PDGF-BB  Hofmann La Roche, Basel 
PDGF-AA Upstate  Biotechnologies (Lake Placid, USA) 
Perchloric acid  Merck, Darmstadt 
Ponceau S  Serva, Heidelberg 
Potassium acetate  Merck, Darmstadt 
Potassium chloride   Roth, Karlsruhe 
Protein A-sepharose 4B CL  Amersham Pharmacia, Freiburg 
Rediprime
TM Random Labelling System  Amersham Pharmacia, Freiburg 
Skim milk (non fat)  Fluka, Deisenhofen 
Salmon Spermine  Calbiochem, Schwalbach 
SDS Merck,  Darmstadt 
Sodium acetate  Merck, Darmstadt  
Sodium chloride   Merck, Darmstadt 
Sodium citrate   Merck, Darmstadt 
Tetramethylethylendiamine (TEMED)  Sigma Aldrich Fine Chemicals, Deisenhofen 
Triton-X-100 Sigma  Aldrich  Fine Chemicals, Deisenhofen 
Tween 20  Sigma Aldrich Fine Chemicals, Deisenhofen 
Xgal Roth,  Karlsruhe 
Yeast extract  Gibco Life Technologies, Karlsruhe 
YC-1   Alexis, Grünberg 
All other solvents and salts were of the highest qualities available and supplied by 
Merck (Darmstadt), Roth (Karlsruhe) or Sigma Biochemicals (Deisenhofen). 
2.1.3 Buffer-Solutions   
2.1.3.1 Buffer for electrophoresis   
TBE-buffer 10x  900 mM Tris borate, 20 mM EDTA 
TAE-buffer 10x  400 mM Tris acetate, 10 mM EDTA 
2.1.3.2 Buffer for cell culture   
PBS-buffer 10x  1.5 M NaCl, 30 mM KCl, 15 mM KH2PO4, 60 
mM Na2HPO4 
2.1.3.3 Solutions for plasmid isolation from E.Coli-bacterials (Quiagen-method) 
Resuspensionbuffer (B1, storage at 4 °C)  50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 
100µg/ml Rnase A 
Lysisbuffer (B2)  200 mM NaOH, 200 mM SDS 
Neutralisationsbuffer (B3):  3 M Potassiumacetat pH 5.5 
2.1.3.4 Buffer for northern blot analysis   
SSC-buffer 20x     3 M NaCl, 300 mM Na2Citrat  
10 x MOPS:  0.4 M MOPS, 0.1 M Na-Acetate, 10 mM 
EDTA 
Denaturation-buffer:  66 µl 10 x MOPS, 316 µl Formamide, 117 µl 
Formaldehyde (37%) 
20 x SSC  175.3 g NaCl, 88.2 g Na-citrate Dihydrate, 
adjust to pH 7.0 with HCL (10N) ad 1 l ddH2O 
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0.02% methylenbluebuffer in 0,5 M 
NaAcetatsolution 
 
68.04 g Na-Acetate-3H2O, solve in 500 ml 
ddH2O, adjust to pH 5.2 with CH3COOH ad 1 l 
ddH2O and autoclave, 200 mg methylenblue 
Hybridisation-buffer 50  ml  Formamid, 12.5 ml 20 x SSC, 5 ml 100 x 
Denhartz, 10 ml 10% SDS, 22.5 ml ddH2O, 
Herrings- sperm-DNA 100 µl to 10 ml solution, 
10 g Dextransulfat 
Washing-buffer I  2 x SSC, 0.1 % SDS 
Washing-buffer II  0.2 x SSC, 1 % SDS 
 
2.1.3.5 Buffer for western blot analysis   
SDS-Electrophoresisbuffer 1x  25 mM Tris, 192 mM Glycine, 0.1 % SDS (pH 
8.3) 
Methanol-Transferbuffer 1x  25 mM Tris, 192 mM Glycine, 20 % Methanol 
(pH 8,3) 
Upper-gel-buffer     125 mM Tris-HCl (pH 6.6), 0.1 % SDS 
Lower-gel-buffer  375 mM Tris-HCl (pH 8.8), 0.1 % SDS 
All buffers were prepared with highly purified water from a Milli-Q-system (Millipore). 
 
 
2.1.4 Primer   
1. PDGFR-α  
PDGFR-α forward 
688 bp 
ATG TTT CTA GAC TCG CAG CTC A 
PDGFR-α reverse  ATA AAC AAA GGC AGT GAT ACA G 
2. PDGFR-β  495 bp 
PDGFR-β forward  TCC AGC TGT GCC TCA GGC TCT G 
PDGFR-β reverse  GAC CAG TTC TAC AAT GCC ATC A 
3. GAPDH  497 bp 
GAPDH forward  CCT TCA TTG ACC TCA ACT AC 
GAPDH reverse  GGA AGG CCA TGC CAG TGA GC 
4. PDGFR-α-Promoter  1723 bp 
PDGFR-α-Promoter forward  GGA GCT CTA AAT CTT GAC TTG CTT TTA 
ACA ACA GC  
PDGFR-α-Promoter reverse  GGG ATC CTT GTT TCA CTC CCT CAA GCT 
CCA ACA GT 
All primers have been purchased by Invitrogen life technologies 
 
 
2.1.5 Antibodies  
anti-PDGFR-α (951): sc-431, rabbit 
polyclonal 
Santa Cruz Biotechnologies, Heidelberg 
anti-PDGFR-β (958): sc-432, rabbit 
polyclonal 
Santa Cruz Biotechnologies, Heidelberg 
anti-pPDGFR-α (pTyr-720) sc-12911-R  
rabbit polyclonal) 
Santa Cruz Biotechnologies, Heidelberg 
anti-PKB-α (Akt-1), sheep polyclonal  Upstate Biotechnologies (Lake Placid, USA)
anti-pAkt (pSer-473): 4E2, rabbit 
Monoclonal 
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anti-rabbit IgG (horseradish peroxidase 
coupled) 
Amersham Pharmacia, Freiburg 
 
2.1.6 Enzymes 
Pfu-DNA polymerase   Stratagene, Heidelberg 
Restriction enzymes  MBI-Fermentas, St. Leon-Rot 
Reverse transcriptase  MBI-Fermentas, St. Leon-Rot 
Taq-DNA polymerase  MBI-Fermentas, St. Leon-Rot 
  
2.1.7 Plasmids   
pBluescript II KS (+)  Stratagene, Heidelberg 
pGL3 Invitrogen,  Heidelberg 
pTOPO TA Cloning Kit  Invitrogen, Heidelberg 
  
2.1.8 Eukaryotic cell lines   
RMC, B1  Preparation of primary cells from rat kidney 
by J. Pfeilschifter, 1991 Frankfurt 
2.1.9 Bacterial strains   
E. coli TOP10F’  Invitrogene, Heidelberg 
 
 
 
 
2.2   Methods 
 
2.2.1 Cell-culture  
2.2.1.1 Thawing of cells 
Cloned mesangial cells (MC), originally isolated from rat kidneys (Pfeilschifter and Vosbeck, 
1991), were used for all experiments. The cell stocks were stored in liquid nitrogen in FCS 
and 20% DMSO containing kryotubes (Nunc). Cells were thawed in a water-bath at 37°C and 
transferred to 175 cm
2 culture dishes (Greiner), containing 25 ml RPMI 1640 culture medium 
supplemented with 10 mM HEPES, 10 % fetal calf serum (FCS), 2 mM glutamine, 5 ng/ml 
insulin, 100 U/ml penicillin and 100 µg/ml streptomycin. The culture dishes were incubated at 
37°C and 5 % CO2. (Heraeus BBD 6220 incubator).The next day fresh medium was supplied 
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2.2.1.2 Cell passaging 
For all experiments cells between passages eight and twenty were used. Before each passage, 
cells were rinsed with PBS (9.1 mM dibasic sodium phosphate, 1.7 mM monobasic sodium 
phosphate, 150 mM sodium chloride, pH 7.4) and then incubated with 4 ml trypsin-EDTA per 
175 cm
2 culture-dish for 3 min at 37°C. Trypsinised MC were centrifuged for four minutes at 
900 rpm  (Heraeus Megafuge 1.0). Afterwards MC were re-suspended, counted using a 
Neubauer chamber and transferred in new culture dishes. For subcultivation 3.3 x 10
6 cells 
per 175 cm
2 culture dish were used. 
 
2.2.1.3 Cell stimulation 
The content of one confluent 175 cm
2 bottle was distributed on twenty 100 mm culture-plates. 
Cells were grown until confluence in 8 ml prepared RPMI 1640 culture medium. 
One day before stimulation, cells were rinsed with PBS and incubated for 24 h with serum 
free Dulbecco’s Minimal Essential Medium (DMEM) supplemented with 0.1 mg/ml of 
bovine serum albumin, 5 ng/ml insulin, 100 U/ml penicillin and 100 µg/ml streptomycin. 
On the day of stimulation cells were rinsed with PBS and 5 ml prepared DMEM was added to 
each Petri dish. Afterwards, NO-donors or other reagents were supplied and cells were 
incubated for the indicated time-periods. 
 
2.2.2 Isolation of total cellular RNA 
Isolation of total cellular RNA was performed with Trizol Reagent
TM (Sigma). MC cultured in 
10-cm dishes were rinsed twice with PBS. After complete removal of residual PBS 1 ml 
Trizol (a mixture of guanidine thiocyanate and phenol) was added to each 10 cm-plate and 
cells were scraped with a rubber policeman. The lysates were transferred into new Eppendorf 
tubes. 200 µl chloroform were supplied and tubes were shaken for 15 sec and incubated for 5 
min at room temperature. Then tubes were centrifuged for 15 min at 13000 rpm at 4 °C. The 
aqueous upper phase was carefully transferred into a new tube and an equal volume of 
isopropyl alcohol was added to precipitate RNA. The tubes were mixed thoroughly, incubated 
for 15 min at room temperature and centrifuged again (13000 rpm, 20 min., 4 °C). The 
supernatant was decanted, the RNA pellet was washed with 500 µl absolute ethanol and 
incubated at 4 °C for 10 min. Afterwards tubes were centrifuged again for 10 min (13000 
rpm, 4 °C). Ethanol was decanted and the precipitated RNA pellet was air dried at 37 °C. The 
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80 °C. RNA concentration was quantified by photometry at a wavelength of 260 nm 
(GeneQuant, Pharmacia, Freiburg Germany).  
 
2.2.3 Quantification of RNA/DNA 
The absorption of RNA/DNA probes were determined with a photometer (Gene Quant II, 
Amersham Pharmacia) at a wavelength of 260 nm, corresponding to the maximal absorption 
rate of nucleic acids. There is a linear correlation between the absorption rate (optical density, 
OD) and RNA/DNA concentration. 50 µg/ml double-stranded DNA or 40 µg/ml single 
stranded DNA and RNA have an optical density (OD) of one (Sambrooke et al., 1989). The 
unknown concentrations of the probes could be calculated by measuring the respective OD 
rate. Proteins have their absorption maximum at wavelength of 280 nm. To control if there is 
any protein contamination in the RNA/DNA probe, the absorption rate at wavelength of 280 
nm was measured as well and the ratio between OD260 and OD280 (OD260/OD280) was 
determined. A ratio between 1.8 and 2 stands for high purity of the RNA/DNA sample. 
Intactness of RNA and exactness of the measured concentration was confirmed on 1% 
agarose gel electrophoresis (3µg per probe).  
 
2.2.4 Agarose gel electrophoresis 
DNA or RNA at about neutral pH is negatively charged due to the phosphate groups of each 
nucleotide. There is a linear correlation between the amount of nucleotides and the ionisation 
state. This charge allows a size-dependent separation of DNA/RNA on agarose gel 
electrophoresis.  
The gel concentration for all analyses was 1%. Agarose was dissolved in 1x TBE and 
ethidium bromide, an intercalating substance that binds to DNA/RNA, was added to a final 
concentration of 500 ng/µl. Ethidium bromide allows the visualisation of bound RNA/DNA 
since it fluoresces under ultraviolet light. The DNA/RNA probes were diluted with loading 
dye (6x loading buffer: 30 % glycerol v/v, 0.25 % bromophenolblue w/v, 0.25 % 
xylenecyanole w/v, 60 % 10x TAE buffer v/v) and loaded to the gel lanes. Electrophoresis 
was performed in 1x TBE buffer with a voltage of 5-10 V/cm gel. DNA fragment sizes were 
estimated using molecular weight markers (MBI Fermentas). 
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2.2.5 Reverse transcription of total cellular mRNA in cDNA 
A DNA replica of mRNA is produced by the enzyme reverse transcriptase. Messenger RNAs 
have a long poly-adenosine tract at their 3’end. This position is used for a small 
oligonucleotide primer (oligo dT), consisting of thymidine nucleotides, to anneal and to give 
the enzyme a starting site to copy the mRNA template. The product is complementary DNA 
of total cellular mRNA.  
5 µg RNA were mixed with the unspecific primer oligo dT (500 ng). Tubes were refilled to 12 
µl with DEPC-H2O centrifuged and incubated for 10 min at 70 °C in the thermocycler to 
enable the annealing of the oligonucleotide. Then probes were cooled on ice and in each tube 
a mixture of 1x First Strand Buffer, 0.1 M DTT, 2 mM dNTP-mix and 40 U Super Script 
Enzyme were added and tubes were incubated in the thermocycler for 60 minutes and 42 °C 
the optimal enzyme temperature. The cDNA probes were stored at –20 °C. 
 
2.2.6 cDNA amplification of PDGFR -α, PDGFR -β and GAPDH 
The polymerase chain reaction (PCR), established by Mullis and Faloona in 1987, allows the 
amplification of a known nucleotide sequence. For PCR two primers (oligonucleotides) are 
needed, in which one primer is complementary to each strand of the DNA double helix. The 
primers lie on opposite sides of the region to be amplified and determine the ends of the final 
DNA fragment.  
For each probe 2 µl of the RT-product (3.4) was utilised. A mixture, which was composed of 
39,5 µl PCR-H2O, 5µl PCR-Buffer (100 mM Tris-HCl, 15 mM MgCl2 , 50 mM KCl, pH 8.3) 
1µl dNTP-mix (2 mM), 1µl forward primer (50 µM) , 1µl reverse primer (50 µM) and 0.5 µl 
Taq-polymerase (0.5 U) was added to each cDNA containing PCR-tube, to a final volume of 
50µl. The tubes were mixed and centrifuged briefly before the thermocycler was started.  
Our reaction began with heating of the probes for 5 min at 94 °C (1 cycle) to denaturate the 
DNA completely. Then the actual 3-phased-PCR-cycle began with the denaturing phase in 
which probes are heated for 30 sec at 94 °C, followed by the annealing phase for 45 sec at 53 
°C and in the last step of the cycle, temperature is elevated for 60 sec to 72 °C – the optimal 
working temperature of Taq polymerase and elongation was initiated. These 3 phases were 
repeated 23 times for the PDGFR-β primers  and 25-times for PDGFR-α primers, PDGFR-α-
promoter primers and for GAPDH primers. The sequence of these primers are listed in 
chapter 2.1.4. The reaction was completed by heating the probes for 7 min at 72 °C (1 cycle). 
The amplification products were stored at 4 °C, centrifuged and analysed by agarose gel 
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2.2.7 DNA-cloning (by TOPO TA Cloning®) 
In this experiment bacteria were transfected with a plasmid that includes the DNA insert, 
which has to be amplified. The product serves e.g. as a hybride for northern blot analysis. 
Plasmids are small circular DNA molecules that replicate independently of the genome. The 
plasmids used for DNA cloning models often encode for a resistance factor against 
antibiotics. E. coli cells that carry such a recombinant plasmid develop into a colony on an 
agar stained with antibiotics. By inoculating a single colony of interest into a liquid culture, a 
large number of identical plasmid DNA molecules - each containing the same DNA insert - 
could be gained. 
 
2.2.7.1 Transfection of E. coli bacteria with PCR-product-containing vectors  
For transfection TOPO TA Cloning Kit (Invitrogen) was utilised. 4 µl PCR-product were 
mixed with 1µl buffer solution and 1 µl TOPO vector. The mixture was incubated for 5 min at 
room-temperature. The PCR product was inserted into the plasmid (TOPO vector) by 
supplemented enzymes. Meanwhile E. coli bacteria (TOP10F’strain) were thawed on ice. 2 µl 
of the 6 µl plasmid mixture was supplemented to 1µl E. coli bacteria and mixed briefly. The 
cell plasmid solution was then incubated for 5 min on ice. Afterwards cells were heated for 30 
sec at 42 °C to make the cell membrane permeable for the plasmids. Then 250 µl SOC 
medium (2 % Tryptone, 0.5 % Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 
mM MgSO4, 20 mM glucose) was supplied and tubes were shaken for 1 h at 37 °C. 100 µl of 
this cell solution were transferred on agar-plates (agar 15 g/l) that were treated with ampicillin 
(50 µl/ml), 50 µl XGAL (1 mg) and 50 µl IPTG (1.25 mg). Plates were incubated over night 
at 37 °C. A resistance factor against ampicillin is inoculated in the plasmid. Therefore only 
plasmid-containing E. coli bacteria were able to grow on the agar plates. Furthermore the 
insertion of PCR-products can be confirmed by the colour of the E. coli colonies. Successful 
insertion interrupts a gene that encodes for an enzyme, which in its intact state metabolises the 
substance X-Gal, leading to a characteristic blue coloration of the colony. Infected E. coli 
colonies that contain a PCR product insert in their plasmids beware their natural white colour. 
For further procedures one white colony was picked up and transferred in a glass tube with 2 
ml N3Y-Broth Medium and ampicillin (50µg/ml).The glass tubes were shaken over night at 
37 °C. 
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2.2.7.2 Mini-preparation of plasmid DNA from E. Coli by Quiagen  
This method serves the separation of amplificated pDNA of experiment 2.2.7.1 
The content of the glass tube of method 2.2.7.1 was transferred into an Eppendorf tube and 
centrifuged for one minute. The liquid phase was discarded and the pellet was re-suspended in 
100 µl resuspension buffer P1 (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 µg/ml RNase 
A). 200 µl lysis buffer (200 mM NaOH, 200 mM SDS) were added to the resolved E. Coli-
cell-solution and the tube was mixed briefly. Then 150 µl neutralisation buffer P3 (3 M 
potassium acetate pH 5.5) was supplied, that lead to precipitation of the proteins. The solution 
was centrifuged for 15 min at 4 °C and the liquid phase was decanted into a new Eppendorf-
tube. 800 µl propanol were added to the liquid phase and the tube was centrifuged again for 
15 min at 4 °C. Propanol leads to precipitation of DNA. The liquid phase could be discarded. 
The pellet was again treated with alcohol - 100 µl 96 % ethanol to clean the DNA- and 
centrifuged for 10 min at 4 °C. The supernatant was discarded and the pellet dried at 37 °C. 
Thereafter the pellet was resolved in 50 µl ddH2O and DNA concentration was measured as 
described. 
 
2.2.7.3 Digestion of mini-Prep-DNA with EcoR I 
This method tests, whether the DNA fragment inserted in the plasmid DNA molecule actually 
is the gene of interest. Restriction enzymes that cut DNA at certain nucleotide sequences were 
used to liberate the cloned insert from the whole plasmid-DNA prepared in experiment 2.2.7.2 
After digestion probes were run on agarose gel electrophoresis together with a DNA 
molecular weight ladder and the size of the liberated DNA fragment was compared with the 
former inserted PCR product. 2µl pDNA, 0.5 µl ECORI, 2 µl Buffer and 15.5 µl ddH2O are 
mixed and the tube is incubated for one h at 37 °C. 4 µl 6x loading dye is applied to the 20 µl 
volume and the probe was run on 1 % agarose gel electrophoresis. 
 
2.2.7.4 DNA extraction of agarose gel  
In method 2.2.8.2 the DNA fragment inserted in the plasmid has been cut out by enzyme 
digestion and the DNA fractions were separated by size via agarose gel electrophoresis. Now 
the DNA fragment of interest was excised out of the gel with a scalpel. To separate pure DNA 
from gel remnants NucleoSpin Extract protocol (NucleoSpin Extract 2 in 1 by Macherey & 
Nagel), was used as described by the manufacturer. The DNA concentration was measured as 
described. 
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2.2.8 Promoter analysis 
For promoter analysis a PCR product of about 1723 bp  (forward primer: GGA GCT CTA 
AAT CTT GAC TTG CTT TTA ACA ACA GC; reverse primer: GGG ATC CTT GTT TCA 
CTC CCT CAA GCT CCA ACA GT) was used.  
 
2.2.8.1 Cloning of PCR products in cloning vector (pTOPO) and luciferase vector 
(pGL3) 
The RT-PCR products were cloned into the TOPO-Cloning Vectors (pCR
® II-TOPO®, 
Invitrogen) as described. After preparation of plasmid DNA, PCR inserts were restricted by 
type II endonucleases and separated from these cloning vectors by gel electrophoresis and 
subsequent gel elution using a column gel extracting kit  (NucleoSpin Extract 2 in 1 by 
Macherey & Nagel), followed by ligation into the prepared luciferase vector pGL3.These 
constructs were used to transfect MC.  
 
2.2.8.2 Reporter gene assay 
To study gene expression, the dual-luciferase reporter assay system from Promega was used. 
For this purpose DNA sequences carrying putative regulatory elements were cloned in front 
of a reporter gene, the luciferase enzyme. By transfection with Effectene transfection reagent, 
newly generated constructs were transferred into the eukaryotic target cells. After transfection 
and stimulation, cells were harvested to measure the amount of synthesized reporter gene 
products. To assess the influence of a certain sequence on PDGFRα-promoter gene 
regulation, reporter gene expression in stimulated and unstimulated cells were compared. 
 
2.2.8.3 Transient and stable transfection of MC 
Transfection of cells was performed using the Effectene transfection reagent (Qiagen, Hilden, 
Germany). Effectene represents a new class of lipid-based transfection reagent that 
spontaneously forms micelle structures. One day before transfection 2x10
5 cells per well were 
seeded in 6-well plates. On the day of transfection MC were 50-80% confluent. The cells 
were washed with PBS before 1.6 ml of DMEM medium was added. Per well, 0.4 µg of 
firefly luciferase reporter vector DNA and 0.1 µg of renilla luciferase control reporter vector 
were mixed with the DNA condensation buffer (EC) and 3.2 µl of enhancer. For stable 
transfection the cells were transfected with the prepared pGL3 plasmids and mixed with the 
DNA condensation buffer (EC) and 3.2 µl of enhancer. The DNA mixture was vortexed for 1 
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reagent were added to the DNA mixture and the tube was vortexed for 10 seconds and 
incubated at room temperature for 10 minutes to allow complex formation. Per well, 600 µl of 
serum-free medium was added to the transfection complex and mixed by pipetting up and 
down. Finally, the transfection complex was added drop-wise onto the cells. The plates were 
swirled gently and incubated for 18 hours at 37°C and 5% CO2. MC were washed with PBS 
and new medium with stimulating reagents was added for 24 hours and thereafter MC were 
harvested. For stable transfection, one day after transfection the medium containing the 
complexes was replaced with fresh complete medium. For this purpose, two days after 
transfection the appropriate antibiotic was added to select for expression of the transfected 
antibiotic-resistance gene. 
2.2.8.4 Luciferase assay 
The luciferase of the Firefly (Photinus pyralis) catalyses the oxidation of luciferin. During 
this reaction photons are released at a wavelength of 562 nm. By employing a luminometer 
(AutoLumat LB953, Berthold) a quantitative measurement of the emitted light was 
performed. Cells were transfected with a luciferase construct, stimulated and harvested in 1x 
Reporter-Lysisbuffer (Promega) as described by the manufacturer. The solutions needed for 
measurement were prewarmed at room temperature. 50 µl of cell extract were transferred into 
5 ml Sarstedt tubes. Subsequently, the reaction was started in the Luminometer by injection of 
100 µl Luciferase-Assay-Reagent (Promega) (20 mM Tricin, 1.07 mM (MgCO3)Mg(OH)2 x 
5 H20, 2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 270 µM Coenzym A, 470 µM 
Luciferin, 530 µM ATP pH 7.8). The emitted light was measured for 10 s with a 
Photomultiplier and expressed in Relative Light Units short (RLUs) by the luminometer, 
representing the firefly luciferase activity. Following this step, 100 µl of stop & glo reagent 
that contains an inhibitor of firefly luciferase and the substrate for renilla luciferase, were 
injected and the light emission was measured again, now representing the renilla luciferase 
activity.  
 
2.2.9 Sequence analysis by ABI-PRISM
TM 
DNA sequencing was performed by the four-colour ABI-Prism 310 Genetic Analyser (PE 
Biosystems) based on the dideoxynucleotide chain termination method (Sanger et al., 1977). 
In the termination labelling mix, the four dideoxy terminators (ddNTPs) were tagged with 
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reactions (A, C, G, T) in one reaction tube. The probes were separated electrophoretically 
using a micro-capillary. As each dye terminator emits light at a different wavelength when  
excited by laser light, all four colours corresponding to the four nucleotides can be detected 
and distinguished within a single run. Raw data were evaluated by the Abi Prism sequencing 
analysis software on a Power G3 Macintosh computer.  
For each PCR-tube 250 ng plasmid DNA, 10 pmol primer and 2 µl BigDyeTerminator Premix 
were mixed with ddH2O to a final volume of 10 µl. The sequencing reaction, was performed 
in a thermocycler (GeneAmp 2400, PE Biosystems) with 25 cycles of the following 
temperature steps: denaturation: 96°C for 10 sec, annealing: 55°C for 10 sec, elongation: 
60°C for 4 min. After termination of the PCR the tube was centrifuged for 15 minutes at 
maximum speed, washed with 250 µl 70% ethanol and air-dried at 37 °C. The pellet was 
resuspended in 25µl template suppression reagent TSR and heated to 95°C for 2 minutes. The 
probe was then transferred into a sequencing reaction tube and sequencing was started. 
 
2.2.10 Northern blot analysis 
Total cellular RNA was isolated as described in chapter 2.2.2. 20 µg RNA diluted in 15µl 
H2O and equal volume denaturing solution (500 µl formamide, 162 µl 37% formaldehyde, 
100 µl  10x MOPS [3-(N-morpholino)-propanesulfonic acid]), were incubated for 15 min at 
60 °C and mixed with 6 µl loading dye. Total RNA was separated according to the size in 0.8 
% agarose formaldehyde gel (200 ml gel consisting of 5 % formaldehyde and 95 % 1x 
MOPS) at 80 V for 4 hours in 1x MOPS buffer. Afterwards gel was washed two times with 
2x SSC for 15 min and transferred to a nylon membrane by capillary drag over night at room 
temperature. 
Next day RNA on the nylon membrane was immobilised with a UV transilluminator (254 nm, 
150 mjoule). The membrane was stained with 0.02 % methylene-blue-solution to control the 
intactness of RNA. The nylon membrane was completely decoloured with washing buffer II, 
placed in a tube with 5 ml hybridisation solution (2.5 ml formamide, 0.5 ml 20x SSC, 0.5 ml 
10 % sodium dodecyl sulfate, 1.5 ml H2O) and incubated in a hybridisation oven with rotation 
for 3 hours at 42 °C. Blots were hybridised with a 688 bp RT-PCR product for PDGFR-α 
(forward primer: ATG TTT CTA GAC TCG CAG CTC A; reverse primer: ATA AAC AAA 
GGC AGT GAT ACA G) and a 497 bp RT-PCR product for GAPDH (forward primer: CCT 
TCA TTG ACC TCA ACT AC; reverse primer: GGA AGG CCA TGC CAG TGA GC). The 
cDNA was amplified by Midi Prep Culture. For radio-labelling the “ready prime” labelling 
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[α-
32P]-dCTP according to the manufacturers instructions. Hybridisation was performed over 
night (14 h) at 42 °C and continuous rotation. Next day the membrane was washed 2x with 
washing buffer I at 42 °C, 2x with washing buffer II at 65°C for 15 min and exposed on a 
Phosphorimager (Fuji).Membranes were re-hybridised with GAPDH. 
 
2.2.11 Western blot analysis 
The Western or immunoblot analysis is used to separate and detect certain proteins out of a 
complex mixture. In the first step the mixture of cellular proteins are separated by size in 
SDS-gel electrophoresis and transferred to a nitrocellulose membrane. Next the membrane is 
incubated with a specific antibody (AB1) that recognises the requested protein. Thereafter the 
membrane is washed several times to remove non-bound AB1 and a second antibody (AB2) 
that binds the bound-AB1 is supplied. AB 2 is labelled with an enzyme e.g. horseradish 
peroxidase that catalysis the supplemented substrate ECL. The chemiluminescent reaction 
blackens a Kodak film and makes the protein bands that are connected to the AB1-AB2-
complex visible.  
 
2.2.11.1 Isolation of proteins 
After the indicated time periods stimulated cells (10 cm dishes) were cooled on ice to stop 
further reactions. Medium was decanted and cells were rinsed with ice-cold PBS. 
600µl of a lysis-buffer-proteinase-inhibitor-mix (62.5 mM Tris pH 6,8, 2% SDS, 5% 
Glycerol, 1mM NaF, 1mM PMSF, 1mM Na3VO4 ,10µg/ml Leu, 10µg/ml Pep (Pepstatin), 
10µg/ml Apro, 10µg/ml Tryp) was added to the cells and the plates were shaken (Heidolph 
duomax 5330) for 5min on ice to incubate the whole plate. The cell-lysates were then scraped 
with a rubber-policeman, transferred to heat-resistant eppendorf-tubes and boiled for 5 min. 
After denaturation tubes were cooled-down on ice. Each tube was sonicated (Sonifier „W-
450“Branson) 3 times for 15 seconds to reduce the viscosity and centrifuged at 13000 rpm for 
five min. The pellet was discarded and supernatant transferred to a new tube. 20 µl was 
aliquoted for protein concentration measurement while the rest was mixed with β-
mercaptoethanol (5 % of total protein-volume) a substance that breaks sulphur-linkages in the 
proteins. Then protein samples were aliquoted and stored at – 80 °C until use.  
 
2.2.11.2 Quantification of protein  
The protein concentration was determined by the Bradford protein assay on 96-well plates 
(Bio-Rad, München, Germany). A standard-curve with 5 different concentrations of BSA II - Materials & Methods                                                                                                         - 34 -                     
reaching from 10 to 50 µg/ml was created. 1µl of every protein sample was diluted in 99 µl 
ddH2O. For determination of the zero value we used the lysis-buffer proteinase-inhibitor mix. 
To each well 100 µl BCA-reagent was supplied, which dyes the solution dependent on the 
protein-concentration. The plate was incubated for 20 min at 56 °C. Thereafter absorption was 
measured by the microplate reader (Biorad) at a wavelength of 595 nm. The standard curve 
was constructed and the concentrations of the protein samples were extrapolated by the 
Microplate Manager 4.0 software (Bio Rad). 
 
2.2.11.3 SDS Polyacrylamid Gel Electrophoreses 
Proteins are charged negatively or positively according to their net amount of charged amino 
acids and the pH of the environment. To obtain an uniform charge protein samples were 
incubated with SDS. SDS is a negatively charged detergent that binds and unfolds protein 
molecules. The extended polypeptide chains uptake SDS according to their size. The inserted 
SDS highly overwhelms the proteins’ intrinsic charge and makes them migrate toward the 
positive electrode in SDS polyacrylamide gel electrophoresis. In the meshes of polyacrylamid 
gel, proteins with high molecular weight run slower than the small ones. Therefore SDS 
polyacrylamide gel electrophoresis allows a size-dependent separation of different cellular 
proteins. Electrophoretic separation of proteins was carried out for SDS polyacrylamide gels 
as originally described by Laemmli (1970).  
The indicated protein amounts (20-50µg) were diluted with equal volume of 2x Laemmli-
buffer (1 ml glycerol, 3 ml 10% SDS, 1.25 M Tris-HCl, pH 6.7 and 1mg bromphenol blue), 
denaturated for 4 min at 95 °C and cooled on ice. Thereafter the samples were loaded to the 
gel lanes. The gel consists of two different concentrated sheets, the upper and the lower gel. 
The upper gel (125 mM Tris-HCl pH 6.8, 0,1% SDS, 0,65 ml polyacrylamide, 25µl 10% 
APS, 5 % Temed) is only half as dense as the lower gel. It enables also high molecular weight 
proteins to move and reach the lower gel almost as fast as smaller-sized polypeptides. The 
lower gel is the actual protein-separating matrix. For the PDGFR we used 8% polyacrylamide 
gels (2,5 ml lower-gel-buffer, 2,7 ml polyacrylamide (30 %), 4,8 ml ddH2O, 50 µl APS, 5 µl 
TEMED). Electrophoresis was performed for 2 ½ h at 25 mA in SDS electrophoresis buffer 
(25 mM Tris, 192 mM Glycine, 0,1 % SDS). 
 
2.2.11.4 Protein transfer to nitrocellulose membrane 
For protein transfer from gel to membrane a semi-dry electro-blotting apparatus was used 
(Trans-Blot SD, Bio Rad). After electrophoresis the upper-gel was removed and the lower gel II - Materials & Methods                                                                                                         - 35 -                     
was rinsed in transfer buffer (20 % methanol, 25 mM Tris, 192 mM glycine; pH 8.3). 2x 6 
Whatman paper and the polyvinylidene difluoride membrane were cut to the size of the lower 
gel and soaked one after another in transfer buffer. The first 6 whatman papers were placed on 
the anode side of the blotting apparatus, followed by the methanol activated membrane. Next 
the gel was positioned on the membrane and the last six whatman papers covered the gel. The 
sandwich was flattened with a rolling pin. The apparatus was closed with the cathode to the 
upper side and the negatively charged proteins migrated down towards the anode and were 
stopped on the nitrocellulose membrane. Blotting was performed at 23 V for 30 min. After 
blotting the success of transfer and was controlled by Ponceau S dye staining (0.2% Ponceau-
S w/v, 3% TCA w/v). Afterwards the membrane was discoloured with ddH2O.  
 
2.2.11.5 Blocking 
After blotting the membrane was exposed to protein containing blocking buffer (10 mM Tris, 
300 mM NaCl, 0,5 % Tween 20, 2 % BSA) to avoid non-specific binding of the antibodies. 
Blocking was performed by shaking the membrane for one hour at room temperature.  
 
2.2.11.6 Immunodetection  
The membrane was incubated with the primary antibody diluted in blocking buffer (rabbit 
anti-PDGFR-α (Santa Cruz, Heidelberg, Germany) in a dilution of 1:200; α-Actin 1:2000, β-
Tubulin 1:2000) and shaken for 16 h at 4°C. Then the blot was washed 5 times for 10 min 
with TBS-T (10 mM Tris, 300 mM NaCl , 0.05% Tween 20) at room temperature and the 
secondary antibody diluted 1:10000 in blocking buffer was supplied. The membrane was 
shaken for one hour at room temperature. Again the blot was washed 5 times for 10 min with 
TBS-T at room temperature. Thereafter, the substrate (ECL) for the enzyme (horseradish 
peroxidase) linked to the secondary antibody was applied on the membrane and a Kodak film 
was positioned hereon. The enzyme metabolises the substrate leading to a chemiluminescent 
reaction that blackens the film. The film was developed (Hyperprocessor, Amersham 
Pharmacia) and scanned (GS 700 Imaging Densitometer, Bio Rad). Scanned film was 
analysed by the Molecular Analyst software from Bio Rad.  
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2.2.12 In vivo analysis 
All in vivo analysis was performed by Dr. Liliana Schäfer from the University of Münster, 
Germany. 
 
2.2.12.1 Experimental design of anti-Thy.1.1 Glomerulonephritis 
The anti-Thy-1 glomerulonephritis (anti-Thy 1-GN) was induced in adult male Wistar rats 
weighing 180-200 g (Charles-River, Sulzfeld, Germany) by a single intravenous injection of 
mouse anti-rat Thy-1.1 IgG, clone OX-7 (BioTrend, Cologne, Germany) dissolved in 18 mM 
sodium phosphate, pH 7.4/0.15 M NaCl (PBS), at a dose of 1 mg/kg b.w. Control animals 
were receiving a single intravenous injection of PBS only. Kidneys were harvested at 2, 4, 8, 
16 and 24 h after induction of Thy-1 nephritis. 
L-N
6(1-iminoethyl)lysine(dihydrochloride), (L-NIL; Alexis Biochemicals, Gruenberg, 
Germany) a selective inhibitor of iNOS was administered intravenously at a dose of 5mg/kg 
b.w. to control and nephritic rats 45 min before anti-Thy 1-GN was induced. Kidneys were 
harvested (n = 3 animals per group) 16 h after injection of the anti-Thy 1.1 antibody or PBS. 
Systolic blood pressure was monitored by tail plethysmography (Byrom et al., 1938). Animals 
were anesthetized with hexobarbital (150 mg/kg). Kidneys were removed and glomeruli were 
isolated by differential sieving according to the method of Spiro (Spiro et al, 1984). Glomeruli 
from each kidney preparation were washed three times, examined by light microscopy (purity 
of isolates >95 %), counted thrice in a Fuchs-Rosenthal chamber and processed for Western 
blotting. Protein concentration was determined using the BCA Protein Assay (Pierce, 
Rockford, IL, USA). 
 
2.2.12.2 Western blot analysis of isolated glomerular tissue  
Glomerular homogenates from each individual rat kidney containing equal amounts of 
glomeruli were heated for 5 min at 95°C in Laemmli buffer, separated on SDS-PAGE (7.5% 
acrylamide gel) and transferred (BioRad, Hercules, CA, USA) to nitrocellulose membranes. 
The membranes were blocked with 3% casein, 1% goat serum and 0.002% Tween 20 in 10 
mM Tris/HCl, pH 7.4/0.15 M NaCl (TBS). The membrane was incubated with the primary 
antibody rabbit anti-PDGFR-α (Santa Cruz, Heidelberg, Germany; in a dilution of 1:500 with 
TBS/1% BSA), for 16 h at 4°C. The secondary antibody, horse-radish peroxidase-coupled 
goat anti-rabbit IgG (Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany, 
dilution 1:5000) was applied for 2 h at ambient temperature. The samples were visualised by 
using the ECL Western blotting reagent kit (Amersham Pharmacia Biotech Europe GmbH) II - Materials & Methods                                                                                                         - 37 -                     
and analysis was performed with IQ Solutions Image Quant software (Molecular Dynamics, 
Uppsala, Sweden). Values are given as means ± SEM from three Western blots representing 
the content of PDGFR-α in 10
3 of glomeruli. 
 
2.2.12.3 Immunohistochemistry 
Kidney tissue samples were fixed in 4% formaldehyde in PBS and embedded in paraffin. 
Sections (4µm) were stained with periodic acid-Schiff reaction and processed for 
immunohistochemical studies by immunoperoxidase techniques (Schaefer et al., 2002 ). Prior 
to incubation with the primary antibody, endogenous peroxidase was blocked with 0.2% 
hydrogen peroxidase in methanol and endogenous biotin was blocked using the Avidin/Biotin 
Blocking Kit (Vector Lab, Burlingame, CA, USA). Primary antibodies included affinity-
purified rabbit anti-human PDGFR-α and anti-human PDGFR-α (Tyr720) phosphorylated at 
Tyr720, which both react with the respective forms of  PDGFR-α of rat origin (both from 
Santa Cruz, dilution 1:200, applied for 1h at 37°C). Unspecific staining was blocked with 
PBS/1% BSA/20% goat serum followed by incubation for 1h at 37°C with an affinity purified 
biotinylated goat anti-rabbit IgG (Vector Lab, dilution 1:200). To complete the sandwich 
technique the conjugate of extravidin-peroxidase (Sigma, Munich, Germany, dilution 1:500) 
was applied for 1h at 37°C and sections were developed with the Diaminobenzidine Substrate 
Kit (Vector Lab). Counterstaining was with Mayer’s hemalaun (Sigma). The specificity of 
immunostaining was tested by omitting the primary antibody and by using non-immune 
serum ”unspecific” IgG.  
 
2.2.13 Statistical analysis 
Means and Standard Deviations were determined. Students’ t-test or ANOVA analysis were 
used to test for statistically significant differences (P values < 0.05).III - Results                                                                                                                                - 38 - 
III - R E S U L T S 
3.1 Effects of Nitric Oxide on PDGFR expression 
The PDGFR is an important signal generator that triggers proliferation and migration of 
glomerular MC (Heldin and Westermark, 1999). Under inflammatory conditions particularly 
the  β-receptor is highly upregulated and contributes to the sclerotic modification of the 
glomerulus (Matsuda et al., 1995). The α-receptor is barely detectable in healthy MC. There 
are strong down-regulatory mechanisms that inhibit the presence of this receptor on the cell-
surface (Abboud et al., 1994). However, glomerular inflammation leads to an increase of 
PDGFR-α expression, indicating a particular role for the alpha receptor under pathological 
conditions (Gesualdo et al., 1991, 1994). Another important mediator participating in the 
course of inflammatory kidney diseases is NO. This molecule regulates many genes and 
proteins (Pfeilschifter et al., 2001; Huwiler and Pfeilschifter, 2003). 
 
3.1.1 Nitric Oxide time-dependently induces PDGFR-α mRNA expression  
To analyse whether the NO pathway also modulates PDGFR expression we stimulated MC 
for different time-periods with or without the NO donor DETA-NO. As shown in Figure 1 
DETA-NO treated cells revealed a marked increase of PDGFR-α mRNA steady-state levels, 
whereas the β-receptor was not or only marginally affected by NO. Therefore, the β-receptor 
subunit was not further analysed in my thesis. 
Fig. 1a 
  
 
 
 
 
 
 
 
 
Fig. 1 : Time-dependency of NO-induced PDGFR-α expression 
Quiescent rat mesangial cells were stimulated with the NO donor DETA-NO (D, 100µM) for the indicated time periods and 
compared to control cells (Co). Total cellular RNA was isolated and reverse transcriptase-PCR was performed for PDGFR-α 
(upper panel), PDGFR-β (middle panel) and GAPDH (lower panel) as described. Results are representative for at least three 
independent experiments giving similar results (Fig. 1a) and are depicted as means +/- SD. * P < 0.05 for D-NO versus Co 
(Fig. 1b).
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3.1.2 Nitric Oxide concentration-dependently induces PDGFR-α-mRNA expression  
We started our analysis with DETA-NO concentrations between 62,5 µM and 500 µM. As presented 
in Figure 2 and 3 the lowest concentration of 62,5 µM DETA-NO was sufficient to increase 
transcription PDGFR-α-mRNA in PCR and Northern blot analysis. 
 
 
  
 
 
 
 
 
 
 
 
 
*  * 
* 
* 
  * 
Fig. 3: Concentration-dependency of nitric oxide 
induced PDGFR-α mRNA steady-state level 
Quiescent rat mesangial cells were stimulated with 
either vehicle (co) or with the indicated concentrations 
of DETA-NO for 8 hours. Total cellular RNA was 
isolated and Northern blot analysis was performed for 
PDGFR-α (upper panel) as described. To correct for 
variations in RNA amount blots were rehybridized 
with GAPDH (lower panel) (n=1). 
Co  62.5   125   250    500 
DETA-NO[µM] 
GAPDH 
PDGFRα 
Co 62.5    125   250     500 
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Fig. 2: Concentration-dependency of nitric oxide 
induced PDGFR-α mRNA steady-state level 
Quiescent rat mesangial cells were stimulated with 
either vehicle (co) or with the indicated 
concentrations of DETA-NO for 6 hours. Total 
cellular RNA was isolated and reverse transcriptase-
PCR was performed for PDGFR-α (upper panel), and 
GAPDH as described. Results are representatives of 
at least three experiments giving similar results. 
Fig. 2 
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Since the Northern blot technique revealed only weak signals also after a long exposition 
period further experiments for the analysis of PDGFR-α mRNA expression were performed 
exclusively by RT-PCR. 
To investigate the consequences of lower doses of DETA-NO we repeated the experiment 
with concentrations between 5 and 500 µM DETA-NO (14 h treatment). As depicted in 
Figure 4 even 5 µM DETA-NO were able to induce PDGFR-α-m-RNA significantly. Higher 
concentrations of DETA-NO reversed the effect or partially even inhibited PDGFR-α- mRNA 
level. This could be due to a potentially cytotoxic effect of high doses of DETA-NO. 
 
Fig. 4a 
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Fig. 4: Concentration-dependency of nitric oxide-induced PDGFR-α m RNA levels 
Quiescent rat mesangial cells were stimulated with or without the NO donor DETA-NO (D) for 14 h with the indicated 
concentrations. Total cellular RNA was isolated and reverse transcriptase-PCR was performed for PDGFR-α (upper panel) 
and GAPDH (lower panel) as described. Signals were quantified densitormetrically. Results are representative for at least 
three independent experiments giving similar results (Fig. 4a.) Values were depicted as means +/- SD. * P< 0.05 for D-NO 
versus Co (Fig. 4b).  
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3.1.3 Nitric Oxide time-dependently increases PDGFR-α protein-level   
The first part of this work demonstrated that DETA-NO elevates PDGFR-α mRNA steady-
state levels. The next step was to analyse whether the surplus of mRNA is also translated into 
protein. Therefore we stimulated cells for different time-periods with 100 µM DETA-NO. As 
demonstrated in Figure 5 there is a significant increase of PDGFR-α protein already after 4 h, 
and peak values are obtained at 12 hours. Afterwards, the amount of PDGFR-α declines back 
to basal level (24h). However, MC do not stringently reply to NO stimulation in the same 
manner. The strength of response for the different time points varies leading to the 
immoderate standard deviations (e.g. the 6h time point). But nevertheless a constant increase 
of PDGFR protein expression in NO-exposed cells in comparison to control was always 
observed between 6h and 16h of treatment when compared to control cells. 
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Fig. 5: Time-dependent induction of PDGFR-α protein expression by nitric oxide  
Quiescent rat mesangial cells were stimulated for the indicated time periods either with vehicle (Co) or with 100 µM DETA-
NO. Total cellular protein was isolated as described. The protein lysates were subjected to SDS-PAGE (8% acrylamid) and 
transferred onto a nitrocellulose membrane. Western blot analysis was performed using a specific PDGFR-α antibody and a 
β-Actin antibody at a dilution of 1:500 and 1:2000 respectively. Bands were detected by the ECL method according to the 
manufacturer’s recommendation and relative units between PDGFR-α and β-tubulin were calculated. Values were depicted 
as percentage of control probes. Data are representatives of three independent experiments giving similar results (Fig. 5a) and 
are expressed as means +/- SD. * P<0,05 for D-NO versus Co (Fig 5b). 
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3.1.4 Nitric Oxide concentration-dependently increases PDGFR-α protein levels  
MC were stimulated with different concentrations of DETA-NO for 14 h.  
As depicted in Figure 6 DETA-NO enhances PDGFR-α protein level with a maximal effect 
between 50 and 100 µM.  
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Fig. 6: Effects of DETA-NO on PDGFR-α protein expression 
Quiescent rat mesangial cells were pretreated either with vehicle (Co) or with the indicated concentrations of DETA-NO for 
14 h. Total cellular protein was isolated. Protein lysates were subjected to SDS-PAGE (8% acrylamide) and transferred to a 
nitrocellulose membrane. Western blot analysis was performed using a specific PDGFR-α antibody and an α-Actin antibody 
at a dilution of 1:500 and 1:2000 respectively. Bands were detected by the ECL method according to the manufacturer’s 
recommendation and relative units between PDGFR-α and α-Actin were calculated. Data are representatives of three 
independent experiments giving similar results (Fig. 6a) and are expressed as means +/- SD. * P<0.05 for DETA-NO versus 
Control (Fig.6b).
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3.2 IL-1ß induces PDGFR-α expression in part by the synthesis of Nitric Oxide 
PDGFR-α is significantly upregulated by exogenously applied NO on the mRNA and protein 
level (Figures 1-6).  
In vivo NO derives predominantly either from macrophages or is synthesized by the inducible 
NO synthase of MC, since MC do not express eNOS or nNOS (Pfeilschifter et al., 1992 ). MC 
are able to induce the iNOS after IL-1ß stimulation that leads to the synthesis of high amounts 
of NO. (Pfeilschifter and Schwarzenbach, 1990) To verify that the induction of PDGFR-α by 
DETA-NO is mimicked by endogenous NO production, cells were stimulated with IL-1β.  
This pro-inflammatory cytokine is one of the major inducers of iNOS expression in rat MC. 
The most important feature for IL-1β mediated iNOS stimulation is the activation of the 
transcription factor NF-κB (Eberhardt et al., 1994; 1998). Also the activity of other 
transcription factors like C/EBPβ and C/EBPδ (CCAAT/enhancer binding protein) is 
triggered by IL-1ß and contribute to iNOS expression and subsequent NO formation 
(Eberhardt et al., 1998). 
Not only iNOS but also PDGFR-α expression is under the transcriptional control of IL-1β. 
Kitami et al. (1995), reported that the IL-1β mediated induction of PDGFR-α in vascular 
smooth muscle cells (VSMC) is due to the activation of the transcription factors C/EBPδ and 
(to a much lesser extent) C/EBPβ (Fukuoka et al., 1999).  
Consequently, there are two IL-1β-mediated molecular mechanism for PDGFR-α induction. 
One comprises the IL-1β-iNOS-NO pathway, the other induction of transcription factors 
which directly associate with the PDGFR-α promoter.  
To discriminate between both signalling cascades, cells were costimulated with 
N
Gmonomethyl-L-arginine (L-NMMA), which is an L-arginine analogue, with a substituted 
guanidine nitrogen group. It inhibits all forms of NO synthases. L-NMMA binds to the same 
binding site as the natural substrate and hinders competitively arginine to associate with the 
enzyme, leading to a dose-dependent reduction of NO formation (Leiper and Vallance, 1998). 
As shown in Figure 7, IL-1β upregulates PDGFR-α protein level. Blocking iNOS activity by 
L-NMMA diminishes the cytokine effect down to 60 % of total activity, but as expected also 
higher concentrations of L-NMMA do not completely reverse the observed induction.  
These results clearly demonstrate that the IL-1β-mediated PDGFR-α induction is at least 
partly due to iNOS induction and subsequent NO formation. III - Results                                                                                                                                - 44 - 
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Fig. 7: Effects of IL-1β and L-NMMA stimulation on PDGFR-α protein expression 
Quiescent rat mesangial cells were stimulated for 24 h with either vehicle (Co) or IL-1β (0.3 nM) in the absence or presence 
of the indicated concentrations of the NOS inhibitor L-NMMA. Total cellular protein was isolated as described. 60 µg of 
protein were subjected to SDS-PAGE (8% acrylamide) and transferred to a nitrocellulose membrane. Western blot analysis 
was performed using specific PDGFR-α and α-actin antibody at a dilution of 1 : 500 and 1 : 2000 respectively. Bands were 
detected by the ECL method according to the manufacturer’s recommendation. Data are representative for three individual 
experiments (Fig. 7a). PDGFR-α and α-actin-bands were evaluated densitometrically and relative units were determined. 
Values were depicted as percentage of IL-1 β stimulation and are expressed as means +/- SD. * P< 0.05 for Il-1β + L-NMMA 
versus IL-1β, 
&P < 0.05 for control versus IL-1ß (Fig. 7b).
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3.3 Molecular mechanisms of Nitric Oxide-triggered PDGFR-α expression.  
NO exerts its actions by using different signalling pathways. It affects genes either directly or 
indirectly via induction or activation of certain mediators. At low concentrations a common 
mechanism is the activation of soluble guanylyl cyclase (sGC). NO binds to iron of a 
prosthetic heme group and induces a conformational change with a 200-fold stimulation of the 
enzyme activity (Stone et al., 1994). The subsequent formation of cGMP causes many of the 
well established effects of NO.  
 
3.3.1 Nitric Oxide induces PDGFR-α expression via activation of the sGC  
To examine whether the induction of PDGFR-α is mediated via the NO-sGC-cGMP axis, 
cells were stimulated with 3-5’Hydroxymethyl-2’-furyl-1-benzylindazole (YC-1). YC-1 was 
identified as a NO independent activator of sGC (Ko et al., 1994) and leads to a tenfold 
increase of enzyme activity. Furthermore, YC-1 sensitises NO-responsive sGC towards NO 
by retarding the deactivation of NO-stimulated sGC (Russwurm et al., 2002).  
The quinoxalin derivative 1H[1,2,4]oxadiazolo[4,3-a]-quinoxalin-1-one (ODQ) is a well 
known inhibitor of NO-sensitive sGC (Garthwaite et al., 1995) and enables the differentiation 
between cGMP-dependent and cGMP-independent effects of NO. ODQ inhibits sGC 
irreversibly by oxidation of its heme iron (Schrammel et al., 1996).  
If the NO mediated induction of PDGFR-α expression is triggered by cGMP formation, YC-1 
will reproduce and ODQ application will reverse the NO effect on PDGFR-α. To address this 
issue MC were stimulated for 14 hours with DETA-NO which elevates PDGFR-α-protein 
expression (Figure 8). The DETA-NO effect was inhibited when MC were preincubated with 
the sGC inhibitor ODQ (200 µM) 15 min before DETA-NO application. YC-1 stimulation on 
the other hand enhanced PDGFR-α protein level, indicating that NO indeed uses the cGMP 
pathway for PDGFR-α-induction.  
Interestingly, PDGFR-α protein translation was stronger in response to YC-1 than to DETA-
NO, although NO is the more effective inducer of sGC activation. This result implies once 
again that there might be other, potentially simultaneously acting negative regulatory 
elements by which NO influences PDGFR-α-activity.III - Results                                                                                                                                - 46 - 
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Fig. 8: Effects of the sGC inhibitor ODQ and the sGC activator YC-1 on PDGFR-α protein expression 
Quiescent rat mesangial cells were stimulated for 14 h with either vehicle (Co), YC-1 (10 µM and 30 µM) or the indicated 
concentrations of DETA-NO with or without the sGC inhibitor ODQ (200 µM). Total cellular protein was isolated as 
described. Protein lysates were subjected to SDS-PAGE (8 % acrylamide) and transferred to nitrocellulose. Western blot 
analysis was performed using a specific PDGFR-α antibody at a dilution of 1 : 500. To correct for variations in protein 
amounts blots were stripped and furthermore treated with a α-actin antibody at a dilution of  1 : 2000. Bands were detected 
by the ECL method according to the manufacturer’s recommendation. Data are representative for three individual 
experiments (Fig. 8a). PDGFR-α and α-actin-bands were evaluated densitometrically and their ratio was determined. Values 
were depicted as percentage of control cells and are expressed as means +/- SD. * P< 0.05 for D-NO, D-NO + ODQ, YC-1 
 versus Co, and § P< 0.001 for D-NO + ODQ versus D-NO (Fig. 8b).
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3.3.2 Analysis of Nitric Oxide-mediated PDGFR-α transcription 
NO affects many genes on the transcriptional level via activation of transcription factors 
(Beck et al., 1998; Pfeilschifter et al., 2001; Eberhardt et al., 2003). To examine whether the 
induction of PDGFR-α expression is mediated at the transcriptional level we cloned the 
PDGFR-α promoter and performed transfection analysis.  
The PDGFR-α promoter sequence of rat has been deciphered by Kitami et al. (1995). The 
promoter is inducible by cyclic AMP and IL-1ß. The induction of promoter activity by cAMP 
is mediated via a C/EBP recognition site. We designed primers that amplify a fragment of 
about 1723 bp genomic DNA related to the 5`sequences of the PDGFR-α gene. The addition 
of recognition sequences for the restriction enzymes SacI and BamII facilitated direct cloning 
into the respective sites of the pGL3 vector that allows to bring the luciferase gene under the 
transcriptional control of the PDGFR-α promoter. The promoter/luciferase construct was 
further on referred to as promPDGFR-α/PGL3. 
MC were transiently transfected with promPDGFR-α/PGL3. Transfected MC were treated 
either with vehicle or with DETA-NO (250 µM). As a positive control we stimulated cells 
with 2mM 8Br-cAMP,  a substance that releases cAMP, which is a known activator of 
PDGFR-α-promoter (Fukuoka et al. 1999, Kitami et al., 1999).  
As depicted in Figure 9, cAMP leads to slight but constant increase of PDGFR-α-promoter 
driven luciferase activity. This verifies that the cloned promoter fragment is functional. NO on 
the other hand does not induce the PDGFR-α promoter activity. By contrast, NO has a slight 
but significant negative regulatory effect on the PDGFR-α promoter activity. These results 
indicate that the NO-dependent induction of PDGFR-α is probably mediated 
posttranscriptionally. Alternatively the 5´flanking region of 1723 bp might be not sufficient to 
trigger NO-induced promoter activity. 
 
 
00 , 511 , 52
Co
D-NO 250 µM
cAMP 2mM
Fig. 9: Effects of NO on PDGFR-α-promoter activity 
Quiescent MC were transfected with the plasmid 
PDGFRα/pGL3 and with the renilla luciferase containing 
plasmid pRL-TK that includes the constitutive TK promoter. 
Thereafter, cells were treated with 8Br-cAMP (cAMP), 
DETA-NO (D-NO) or vehicle(Co) as indicated for 24 hours. 
MC were then harvested and beetle and renilla luciferase 
activities were assayed using the dual luciferase kit in a 
luminometer. Luciferase values were corrected for renilla 
activity. Values were depicted as percentage of control cells 
and are expressed as means +/- SD. * P < 0.05 for cAMP, 
DETA-NO versus Control. 
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3.4. Functional relevance 
NO regulates PDGFR-α expression on the mRNA and the protein level. The activity of the 
newly synthesized protein was examined by analysing the phosphorylation status of the 
receptor and of the downstream effector molecule PKB/Akt.  
 
3.4.1 Induction of PDGFR-α protein expression permits its enhanced phosphorylation 
Binding of the ligand leads to dimerization and autophosphorylation of PDGF receptors. In 
general, the number of PDGFR-α in rat MC is very low and therefore, the amount of the 
phosphorylated form (pPDGFR-α) was also expected to be hardly detectable, when exposed 
to PDGF. An upregulation of the protein might also increase the accessibility of the receptor 
for its ligand and cause an enhanced autophosphorylation and activation of downstream 
signalling molecules.  
To confirm the functionality of the newly synthesized PDGFR-α cells were preincubated with 
the indicated concentrations of DETA-NO for 14 h. Thereafter PDGF-BB that binds and 
activates both receptor subunits was applied to all plates for the next 15 min. Western blot 
analysis was performed with an antibody specific for the phosphorylated tyrosine residue 720 
of PDGFR-α. As depicted in Figure 10 DETA- NO preincubation leads to an increase of 
pPDGFR-α, demonstrating that higher expression of the PDGFR-α is followed also by a 
higher phosphorylation rate. 
 
Fig. 10 
 
 
 
 
 
 
 
Fig. 10: Nitric oxide triggers PDGFR-α protein expression enables and its phosphorylation  
Quiescent rat mesangial cells were pretreated either with vehicle (Co) or with the indicated concentrations of DETA-NO for 
14 h. Thereafter cells were stimulated with  PDGF-BB (20 ng/ml) for 15 min. Total cellular protein was isolated as described. 
The protein lysates were subjected to SDS-PAGE (8% acrylamide) and transferred to nitrocellulose. Western blot analysis 
was performed using a specific antiphospho-Tyr
720 PDGFR-α antibody and a α-Actin antibody at a dilution of 1 : 500 and 1 : 
2000, respectively. Bands were detected by the ECL method according to the manufacturer’s recommendation and relative 
units between PDGFR-α and α-actin were calculated. Data are representatives of three independent experiments giving 
similar results (Fig. 10a) and are expressed as means +/- SD. * P< 0,05 for DETA-NO versus Control (Fig. 10b).
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3.4.2 Nitric Oxide-triggered induction of PDGFR-α augments PKB phosphorylation  
The NO induced increase of basal PDGFR-α protein level enhances the amount of 
phosphorylated receptor, when incubated with an appropriate ligand and consequently more 
docking sites for potential target molecules including PI3K become available.  
PI3K is one of the most important mediators of PDGF-induced MC proliferation. Inhibition of 
PI3K dose-dependently diminished mitogenic and migrative effects of PDGF down to basal 
level (Ghosh-Choudhury et al., 1997). Activation of PI3K is essential for phosphorylation of 
protein kinase B (Franke et al., 1995). PKB (also referred to as Akt) is a serine/threonine 
protein kinase that exists as three distinct isoforms, PKB-α, PKB-β and PKB-γ Since the 
PKB-α isoform is the most common in MC, immunoblot analysis were performed with a 
PKB-α specific antibody. 
Once phosphorylated PKB in turn catalyses the phosporylation and inactivation of the 
proapoptotic substrate Bad and caspase-9 and thus promotes survival signals (Coffer et al., 
1998). To examine whether NO might alter the phosphorylation status of PKB by induction of 
PDGFR-α, cells were preincubated with the NO donor DETA-NO or vehicle for 14 h and 
then stimulated with PDGF-AA (30ng/ml) for 8 min. Since PDGF-AA is incapable to activate 
PDGFR-β, the obtained effect can only be caused by PDGFR-α. 
PDGF-BB (20 ng/ml) 15min 
DETA-NO [µM] 14 h 
*  *  * 
* 
 * 
* 
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Western blot analysis was performed with an antiphospho-antibody specific for the 
phosphorylated serine-473 of PKB and with an antibody against PKB-α, to correct for 
variations in protein loading. Figure 11 reveals that there are very low amounts of 
phosphorylated PKB in untreated MC. NO alone does not change pPKB level either. 
PDGF-AA on the other hand is a potent initiator of PKB phosphorylation. It leads to a 
twofold increase of the pPKB level. Preincubation with NO in combination with PDGF-AA 
treatment amplifies the PDGF-AA effect threefold, indicating that the surplus of docking sites 
gained by transcriptional induction of PDGFR-α is actually utilized and functionally active. 
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Fig. 11: Effects of NO prestimulation on PDGF-AA-induced PKB-α phosphorylation 
Quiescent rat mesangial cells were pretreated with 100 µM DETA-NO or vehicle for 14 hours, prior to stimulation with 
either vehicle or PDGF AA (30 ng/ml) for the lasting 8 min. Total cellular protein was isolated as described. 60 µg of protein 
were subjected to SDS-PAGE (10 % acrylamide) and transferred to a nitrocellulose membrane. Western blot analysis was 
performed using specific antiphospho-Ser
473  –PKB and total PKB-α antibodies at dilutions of 1 : 1000 and 1 : 2000, 
respectively. Bands were detected by the ECL method according to the manufacturer’s recommendation. Relative units 
between pPKB and PKB were determined. Values are depicted as percentage of control probes. Data are representatives of 
three independent experiments giving similar results (Fig. 11a) and are expressed as means +/- SD. * P < 0.05 for NO, PDGF, 
NO + PDGF versus Control and § P< 0.05 for NO + PDGF versus PDGF (Fig. 11b). 
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3.5 In vivo examination of PDGFR-α-expression in an inflammatory model of anti-
Thy1.1 nephritis  
To investigate whether the in vitro observed data could also be confirmed in vivo a 
cooperation with Dr. L. Schäfer from the University Münster was started. Dr. Schäfer is 
familiar with the inflammatory model of anti-Thy.1.1 nephritis and performed all in vivo 
analyses.  
The anti-Thy-1 glomerulonephritis (anti-Thy 1-GN) was induced in adult male Wistar rats by 
a single intravenous injection of mouse anti-rat Thy-1.1 IgG, whereas control animals were 
receiving PBS only. L-N
6-1-iminoethyl lysine dihydrochloride, (L-NIL), a selective inhibitor 
of iNOS, was either omitted or administered intravenously to control and nephritic rats 45 min 
before anti-Thy 1-GN was induced. Kidneys were harvested (n = 3 animals per group) 16h 
after injection of the anti-Thy 1.1 antibody or PBS and glomeruli were isolated and processed 
as described (Spiro, 1984).  
 
3.5.1 L-NIL decreases PDGFR-α protein expression in anti-Thy.1.-GN 
Western blot analysis was performed with a PDGFR-α-antibody. As depicted in Figure12 
injection of anti-Thy.1.1 antigen induces PDGFR-α expression by approximately twofold. 
Coapplication of the selective iNOS inhibitor L-NIL diminishes PDGFR-α protein level 
(Figure 12), indicating that iNOS acts as the major inductor of PDGFR-α expression in this 
GN model.  
Fig. 12  Fig. 12: Western blot for PDGFR-α in isolated 
glomeruli from control and THY 1-GN rats  
Panel A shows a Western blot for PDGFR-α in equal 
amounts of isolated glomeruli from control and nephritic 
rat kidneys with and without administration of L-NIL as 
indicated. In panel B the quantification of Western blots 
for PDGFR-α (three samples in each group) is given as 
optical density (OD) from 10
3 glomeruli (means ± SEM). 
Significant differences between THY 1-nephritic and non-
nephritic glomeruli are indicated by an asterisk positioned 
directly over the bar. The asterisk between grey and and 
striped grey bars indicates statistical differences between 
THY 1-nephritic glomeruli with or without L-NIL 
treatment, p<0.05.  
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3.5.2 L-NIL decreases the phosphorylation rate of PDGFR-α in anti-Thy1- GN 
Immunohistochemistry was performed for phosphorylated and unphosphorylated PDGFR-α-
protein. As shown in Figure 13 expression of PDGFR-α-and pPDGFR-α-protein is very low 
in glomeruli of control animals. Thy 1.1 glomerulonephritis causes a strong staining within 
the capillary tuft, which apparently represents GMC expressing PDGFR-α protein. 
Again coapplication of the iNOS inhibitor L-Nil was able to reduce PDGFR-α and pPDGFR-
α expression in rats treated with Anti-Thy.1.1-IgG.  
In particular, the increase of PDGFR-α phosphorylation points to a critical role of PDGFR-α 
in GN. Figure 13 clearly shows that this upregulation is mainly due to enhanced iNOS 
expression, since inhibition of iNOS counteracts PDGFR-α protein elevation. 
In summary, the work of Dr. Schäfer verifies our previously observed in vitro data and 
demonstrates that NO acts as potent mediator of PDGFR-α gene expression also in vivo. 
 
Fig. 13 
 
 
Fig. 13: Immunostaining for PDGFR-α (upper panel) and p-PDGFR-α (Tyr720) (lower pannel) in glomeruli from 
control and THY 1-GN kidneys 16h after the induction of nephritis.  
In THY 1 nephritis there was increased mesangial staining for PDGFR-α (upper panel, brown color) and its phosphorylated 
form (lower panel, brown color) 16h after induction of disease. Pretreatment with L-NIL reduced the intensity of staining for 
the phosphorylated and unphosphorylated PDGFR-α. There was no difference in controls receiving L-NIL or vehicle. 
Negative controls, shown here in a tissue section from a THY 1 nephritic kidney as an example, were performed by omitting 
the primary antibodies. The bar indicates magnification.IV - Discussion                                                                                                                          - 53 -                   
I V – D I S C U S S I O N 
 
 
NO is one of the most versatile molecules involved in inflammatory processes. Due to its 
diverse reaction partners like other inorganic molecules, DNA structures, prosthetic groups of 
proteins such as enzymes and transcription factors, NO impacts on many signalling pathways 
and exerts a wide range of effects (Beck et al., 1999; Bogdan, 2001; Huwiler and Pfeilschifter, 
2003). The role of NO in inflammatory processes is controversially discussed. Beneficial as 
well as detrimental consequences of NO-presence in inflammatory diseases have been 
reported (Beck et al., 1999). We believe that the variability of NO action empowers this 
molecule not only to interfere in the disease process but also to regulate and initiate crucial 
turning points in the course of glomerulonephritis (Pfeilschifter et al., 2002; Pfeilschifter, 
2002). 
The experimental model of anti-Thy.1.1 nephritis is a convenient model to analyse the 
mechanisms of inflammatory disease progression. In principal, it is composed of three phases: 
mesangiolysis (first day after disease induction), mesangioproliferation (day 4-10) and 
resolution of the disease (weeks 4-8) (Goto et al., 1995). The mesangiolytic phase is 
associated with high concentrations of NO (Goto et al, 1995). At this stage NO acts as a 
potent inducer of MC death (Narita et al., 1995) and is capable to reduce survival signalling 
e.g. by inhibition of PKB phosphorylation (Rölz et al., 2002). Nevertheless, NO may also 
simultaneously deliver proliferative signals, as it diminuates significantly the expression of 
the potent PDGF scavenger SPARC (Walpen et al., 2000), with a maximal protein reduction 
at a time when maximal NO concentrations can be measured (day 2 after disease induction) 
(Pichler et al., 1996; Walpen et al. 2000). Inhibition of SPARC leads to enhanced availability 
of the potent proliferative growth factor PDGF. Therefore, NO does not only trigger MC loss 
in the mesangiolytic phase but might also be able to prepare the next phase of anti-Thy.1 
nephritis.  
The mesangioproliferative phase begins with the immigration of extraglomerular MC of the 
juxtaglomerular apparatus into microaneurysmal areas in the glomerulus (Hugo et al, 1996). 
Subsequently mesangial hyperplasia can be observed with a maximal quantity of cells at day 
five after disease induction. The MC number at this stage of the disease exceeds the normal 
values two or three times (Jefferson and Johnson, 1999). A lot of mediators have been 
identified that induce MC proliferation, whereby PDGF is regarded as the most potent 
stimulant (Johnson et al., 1992; Jefferson and Johnson, 1999). Mechanisms that lead to the 
decrease of MC number and resolution of the disease are not so well investigated so far. One IV - Discussion                                                                                                                          - 54 -                   
way to restrict further MC proliferation comprises the inhibition of pro-inflammatory or the 
induction of anti-inflammatory mediators that neutralize or antagonize inflammatory signals. 
The increase of SPARC at day 5 after disease induction and the subsequent reduction of 
available PDGF is just one example for a self-defence process of the glomerulus (Pichler et 
al., 1996; Walpen et al., 2000). A vast number of other anti-inflammatory substances have 
been described that contribute to or maintain the onset of the glomerular self-defence system, 
whereby NO participates in regulating the gene-expression of numerous of these mediators 
(Kitamura and Fine, 1999). Additionally, a continuous elimination of MC by apoptosis can be 
observed. This latter mechanism is essential for the diminution of MC cell number back to 
normal values and enables the restructuring of the glomerulus (Tomooka et al., 1992; Baker et 
al., 1994; Jefferson and Johnson, 1999). 
Elucidating the control mechanisms that lead to this orderly repair process and determining 
the relevance of NO action in this context is part of the research effort of the Institute of 
Pharmacology and Toxicology in Frankfurt.  
Generally low amounts of NO are regarded as protective against inflammatory tissue damage 
(Pfeilschifter et al., 1995, 2001), whereas high doses of NO are known to induce apoptosis 
and necrosis in many cell types (Meßmer et al., 1994; Meßmer and Brüne, 1996; Mühl et al., 
1996; Brüne et al., 1998). However, during inflammatory diseases the concentration range of 
NO is wide and resulting effects of NO do not simply depend on the measured absolute 
amount of the molecule, but also of its temporal and spatial distribution (Grisham et al., 1999; 
Pfeilschifter et al., 2001; 2002). Since NO is a gas it diffuses from its source easily and dilutes 
its concentration proportionally to the distance (Grisham et al., 1999). Therefore, also high 
concentrations of NO as produced by iNOS under inflammatory conditions are able to exert 
or initiate somehow protective effects by affecting targets outside of the high-dosed toxic 
area. 
Another important aspect for the resulting net effect of NO concerns the availability of 
potential reaction partners such as reactive oxygen species (ROS). The reaction of NO with 
ROS like superoxide (O2
-)
 or hydrogen peroxide (H2O2) shifts the NO action towards the so 
called indirect effects (nitrosation, nitration, oxidation) that are supposed to be responsible for 
the destructive proinflammatory features of NO (Grisham et al., 1999). Nevertheless the 
consequences of NO/ROS interaction depend mainly on the ratio between NO and ROS and 
does not have to be necessarily harmful. NO is even able to counteract the oxidative stress 
imposed by ROS to the cellular system (Sandau et al, 1997; Pfeilschifter et al, 2002).  IV - Discussion                                                                                                                          - 55 -                   
In MC, ROS are mainly produced by enzymes that are constitutively expressed, e.g. xanthine 
oxidase, cyclooxygenases, nicotinamide adenine dinucleotide phosphate-oxidase (NADPH-
oxidase) but also by iNOS (Pfeilschifter et al., 2001).  
Importantly, the production of ROS and NO does not arise simultaneously. In anti-Thy.1.1 
GN the generation of ROS starts briefly after disease induction, whereas synthesis of iNOS 
commences with a delay of a few hours (Goto et al., 1995). With the increase of NO-
production, ROS synthesis declines and direct NO modulated effects dominate (Pfeilschifter 
et al., 2002). In this context the diminution of ROS-levels is directly mediated by NO altering 
the cellular redox-system: NO downregulates the main ROS producing enzymes NADPH-
oxidase (Clancy et al., 1992), xanthine-oxidase (Lee et al., 2000) and induces protective 
antioxidant enzymes like copper/zinc superoxide dismutase (Cu/ZnSOD) (Frank et al., 1999) 
or manganese SOD (Keller et al., 2003). Another mechanism how NO supports the cellular 
protection system is by inhibition of the iNOS enzyme activity. Although NO is an effective 
inducer of iNOS expression, it inhibits particularly at high concentrations the NOS enzymatic 
activity and limits, therefore, its own synthesis (Mühl and Pfeilschifter, 1995).  
An important mediator that contributes to the inhibition of iNOS expression is PDGF. PDGF, 
that is either released by platelets or secreted by mesangial and other glomerular cells, 
impedes iNOS activity (Pfeilschifter 1991) via activation of protein kinase C (Mühl and 
Pfeilschifter, 1994; Kunz et al., 1997). 
My present study was done to elucidate the role of NO on the PDGF signalling system, the 
main mediator of inflammatory proliferation of rat MC (Johnson et al., 1993; Abboud 1995). 
To this end, the regulation of PDGF ligands and receptors by NO was examined. The only 
component of the PDGF system that was significantly modulated by NO in its expression was 
the PDGFR-α. This induction of PDGFR-α expression is mediated via activation of the NO-
sensitive soluble guanylyl cyclase (sGC). The newly synthesized receptor is functionally 
active and responds in turn to its natural ligand with autophosphorylation and activation of 
downstream effector molecules like protein kinase B (PKB). PKB is a major initiator of 
survival and antiapoptotic signalling (Kaufmann-Zeh et al., 1997). The NO-modulated 
induction of PDGFR-α expression was confirmed in an in vivo model of anti-Thy.1.1 
nephritis and clearly demonstrates that inhibition of iNOS by the iNOS-specific inhibitor L-
NIL reduces PDGFR-α expression as analysed by immunohistochemistry and Western blot 
analysis.  
Taken together, we showed that NO consistently induces the expression of PDGFR-α in vitro 
and  in vivo. By contrast, the PDGFR-β is not or only marginally affected by NO. The IV - Discussion                                                                                                                          - 56 -                   
differential regulation of both receptors is of pathophysiological importance, since MC 
produce and secrete mainly PDGF-AA and PDGF-AB (Betsholtz et al. 1986, Abboud et al., 
1987, Pfeilschifter and Hosang, 1990). Both ligands require the α-subunit for receptor 
dimerization (Heldin and Westermark, 1999). Under physiological conditions MC express 
very low amounts of the α-subunit (Abboud et al., 1994). The induction of this receptor in 
combination with the continuously expressed ligands may permit autocrine stimulation and 
consequently proliferation of MC. Interestingly, the NO-mediated up-regulation of PDGFR-α 
expression is attained at low doses of DETA-NO, which usually characterizes processes 
evoked by cGMP (Moncada et al., 1991).  
Our in vitro and in vivo study revealed that MC respond to NO stimulation with significant 
upregulation of PDGFR-α mRNA and protein expression within 4 hours. The increase of the 
PDGFR-α protein enables PDGF-AA to dimerize and activate PDGFR-αα complexes. 
PDGF-AA is regarded as an ineffective mediator of proliferation, migration and autoinduction 
of PDGF chains in human MC (Abboud et al., 1994, Ghosh-Choudhury et al, 2000). 
However, Abboud and colleagues investigated unstimulated MC, in which the α-receptor is 
chronically downregulated by a constant PDGF-AA secretion. The induction of the receptor, 
that occurs for example upon inflammation, may change the potency of PDGF-AA action in 
MC. 
As shown here, induction of the α-receptor creates more binding sites and leads to enhanced 
delivery of down-stream signals e.g. activity of PI3K. The observation that PKB 
phosphorylation by PDGF-AA was more effective in NO stimulated cells than in the 
unstimulated control cells, reveals that the magnitude of the proliferative potency of PDGF-
AA is limited somehow by the amount of receptors expressed on the cells. 
Whether the NO-mediated elevation of PDGFR-α subunit is actually sufficient to initiate 
proliferation or migration in response to PDGF-AA stimulation has to be clarified in further 
experiments. 
PDGF-AA is not the only isoform that necessitates PDGFR-α monomers to associate. PDGF-
AB as well requires the α-receptor for high affinity binding. It dimerizes PDGFR-ββ 
complexes only at unphysiological high concentrations (Seifert et al., 1993). PDGF-AB is a 
potent mitogenic growth factor for MC. It delivers proliferative and migrative actions and 
induces PDGF-A and B-chain expression thereby setting the basis for an autoinductive 
stimulation circle in MC (Abboud et al., 1994). 
Furthermore, PDGF-AB is the predominant isoform in human serum in contrast to other 
species, in which PDGF-BB is the main but not the only isoform present (Bowen-Pope et al., IV - Discussion                                                                                                                          - 57 -                   
1989). Although, platelets and macrophages synthesize PDGF, the MC is regarded as the 
primary source of PDGF in GN (Jefferson and Johnson 1999).  
Most PDGF-producing cell types secrete PDGF-AA or PDGF-AB and to a much lower 
extent, if at all, PDGF-BB. MC express constitutively PDGF-β receptors, but secrete 
inadequate amounts of its ligand PDGF-BB. In addition, they sufficiently secrete PDGF-AA 
or –AB but barely express the α-receptor. It seems as if there is a natural, reciprocal 
expression pattern between receptors and their corresponding ligands. The increase of PDGF-
BB or PDGFR-α expression may easily disturb this balance and shift it towards proliferation 
and cell survival. Since PDGF-BB is only secreted inadequately at least at the beginning of 
the disease, induction of PDGFR-α and subsequent activation by PDGF-AB and PDGF-AA 
might be of pathophysiological significance. However, the PDGFR-β subunit is, once 
activated, definitely the stronger mitogenic signal device in MC and most other cell types 
(Abboud et al., 1994; Ghosh-Choudhurry et al., 2000).  
The biological activity of the somewhat less potent α-receptor is also less well investigated so 
far. Nevertheless, a consistent upregulation of PDGFR-α under inflammatory diseases has 
been observed (Gesualdo et al., 1994). The pathophysiological relevance of the α-receptor in 
the course of mesangioproliferative glomerulonephritis is gaining recognition.  
The recent discovery of the novel PDGF isoform PDGF-CC (Li et al., 2000) contributed to 
the growing interest. PDGF-CC binds and dimerizes PDGFR-αα and -αβ subunits, but it is 
unable to activate ββ complexes. The mitogenic capability of this isoform is comparable to 
that of PDGF-AB with the difference that higher concentrations are needed for receptor 
activation (Gilbertson et al., 2001).  
The activation of PDGFRs by PDGF-CC might differ from the known other isoforms, since 
the phenotype of PDGFR-α gene deleted mice diverges widely from PDGFR-β
-/- or PDGF-A 
chain and B chain double knockouts, indicating that eventually this new isoform evokes other 
effects (Betsholtz et al. 2001).  
Eitner et al. (2002) investigated the gene expression of PDGF-C chain in normal and diseased 
adult rat kidney. They demonstrated that in the healthy kidney PDGF-C chain expression is 
limited to several cell types including vascular smooth muscle cells and tubulointerstitial cells 
of the collecting duct. By contrast, in the course of various inflammatory kidney diseases e.g. 
the anti-Thy-1.1 nephritis, PDGF-C chain expression is markedly up-regulated also in other 
cells. With the beginning of the mesangioproliferative phase MC are a major source for 
PDGF-C chain synthesis, indicating the participation of this novel PDGF isoform in the 
course of the disease. The functional relevance of PDGF-C chain still is under investigation. IV - Discussion                                                                                                                          - 58 -                   
Apart from its potential mitogenic and fibrogenic effects, PDGF-C is also known to stimulate 
effectively angiogenesis and may contribute to oncogenicity in several sarcoma cell lines 
(Zwerner et al., 2001). 
All effects exerted by PDGF-CC are due to activation of at least one PDGFR-α subunit. The 
induction of the weakly expressed PDGFR-α by NO provides the basis for PDGF-CC 
promoted activation of PDGFRs. The functional relevance of PDGF-CC in the course of 
glomerulonephritis definitively needs to be clarified in future investigations. 
In contrast to many human forms of mesangioproliferative glomerulonephritis the animal 
model of anti-Thy.1.1 nephritis completely resolves several weeks after injection of the 
antibody. The scheme composed of the three disease phases: mesangiolysis -
mesangioproliferation – resolution, with complete restitution of the glomerulus occurs always 
in the same ordered manner. Understanding the control mechanisms that lead to the organized 
reconstitution of the glomerulus and their temporal and spatial appearance in the course of the 
disease may provide the basis for the establishment of effective pharmacological interventions 
in inflammatory kidney diseases.  
One pharmacological approach to dampen inflammatory disease activity in 
mesangioproliferative glomerulonephritis was attempted via the inhibition of the PDGF 
system. The high mitogenic potency of PDGF initiated the development of multiple PDGF-
antagonists that affect either the ligand, its receptor or downstream signalling molecules 
(Heldin et al., 1998). Among them the specific PDGF-B aptamer (Ostendorf et al., 2001), 
widely attained attention. Glomerulonephritis and chronic inflammatory renal diseases still 
are the most common causes for renal failure requiring dialysis or organtransplantation. 
Obviously inhibition of the most potent PDGF isoform is not sufficient to stop the progression 
of disease.  
It is worth noting, that PDGF also exerts beneficial effects, since it initiates tissue remodelling 
and repair (Abboud, 1995). The excessive upregulation of PDGF and its receptors by 
cytokines, growth factors and other inflammatory mediators in a pathological milieu leads to 
the well-known pathogenic effects of platelet-derived growth factor. Therefore, detection and 
neutralization of the regulatory elements responsible for overshooting PDGF activity may 
prevent the problem straight from the beginning.  
Nevertheless a certain degree of MC proliferation is required to repair glomerular injury. As 
indicated, the physiological procedures that regulate the switch between MC loss and MC 
hyperplasia (or vice versa) are incompletely understood so far. NO is supposed to play a key-
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nephritis NO is produced in high concentrations. At this stage NO induces effectively 
cytotoxic and anti-proliferative signalling. One can imagine that NO counteracts its own 
effects by changing the expression of diverse proliferative and protective mediators that 
reconstitute the glomerulus and initiate the proliferative state of the disease. The observed 
induction of PDGFR-α by NO described in my thesis may be one mechanism underlying the 
controlled repair process responsible for the switch between mesangiolysis and 
mesangioproliferation in anti-Thy.1.1 nephritis. 
Since NO is regarded as one of the major players in mesangioproliferative glomerulonephritis, 
inhibition of iNOS became a central mission in NO-research. 
Numerous non-selective as well as several more or less selective iNOS inhibitors were 
identified (Pfeilschifter et al, 1996; Alderton et al., 2001).  
One of the earliest iNOS inhibitors found were the glucocorticoids (Pfeilschifter & 
Schwarzenbach 1990). Glucocorticoids are potent immunosuppressive agents, that inhibit 
inflammatory mediators like IL-1 (one of the main inducers of iNOS expression) generally on 
their transcriptional level. Interestingly, the glucocorticoid mediated inhibition of iNOS is 
additionally attained by post-transcriptional and posttranslational modifications, including a 
decreased protein translation and an increased degradation of iNOS protein. The beneficial 
effects of glucocorticoids in several non-infectious inflammatory kidney diseases are well 
documented (Friedmann et al., 1982) and the observed glucocorticoid-mediated iNOS-
inhibition may contribute to these positive effects in glomerulonephritis.  
Cyclosporin which is a further immunosuppressive agent was also found to inhibit iNOS 
expression (Mühl et al., 1993; Kunz et al., 1995). Cyclosporin A, cyclosporin G and even 
cyclosporin H, a derivate that is devoid of immunosuppressive activity, are able to suppress 
IL-1β-induced elevation of iNOS mRNA level (Pfeilschifter et al., 1996). There are lots of 
other substances that diminish NO production (Pfeilschifter et al, 1996; Alderton, et al., 
2001), manipulation of the L-arginine-NO pathway is the most common mechanism to 
attenuate NO synthesis in experimental models. L-arginine is the natural substrate of all NOS 
isoforms. Substrate depletion, attained via the administration of arginase, an enzyme that also 
metabolises L-arginine (Waddington et al., 1996) or competitive inhibition of NOS by non-
active arginine analogues like N
G-monomethyl-L-arginine (L-NMMA) or L-arginine-
methylester (L-NAME) that compete with the natural substrate for binding (Drapier et al., 
1986; Palmer et al., 1987), are two effective methods to block NO synthesis. The unspecific 
NOS inhibition by both inhibitors, worsens the course of the disease (Waddington et al., 
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simultaneously occurring inhibition of eNOS and the subsequent diminuation of GFR 
(Goligorsky, 1999).  
The development of NOS inhibitors that bind iNOS with higher affinity than the constitutive 
NOS isoforms like aminoguanidine (Corbett et al., 1992; Misko et al., 1993) or L-N
6-(1-
iminoethyl)lysine (L-NIL) (Moore et al., 1994) and their examination in in vivo models of 
glomerulonephritis strengthened the idea that the specific inhibition of iNOS ameliorated 
disease progression (Bremer et al, 1997). However, there is increasing evidence that the 
consequences of iNOS-downregulation do not always have to be positive. Gabbai et al. (1997) 
reported that the administration of aminoguanidine or L-NIL in an in vivo model of interstitial 
nephritis increased tubular injury, which could be confirmed also by others and in additional 
nephritis models (Gopala et al., 2001; Westenfeld et al., 2002). Moreover Gabbai et al., 
(2002) assumed a biphasic effect of iNOS derived NO in the course of disease, with an 
aggravation at the beginning and an amelioration at the later phases of glomerulonephritis. 
These findings emphasize the protective role of iNOS for the resolution of disease. Moreover, 
they are in line with reports from our Institute of Pharmacology and Toxicology in Frankfurt 
(Frank et al., 2000) and illustrate once again that uncoordinated inhibition of NOS without 
regarding the pathophysiological background will not provide an optimal strategy to treat 
glomerulonephritis.  
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V – S U M M A R Y 
 
Nitric oxide (NO) modulates Platelet-derived growth factor receptor-α (PDGFR-α) 
expression in rat renal mesangial cells  
NO, a diffusible gas with various physiological and pathological properties, is synthesized by 
three different forms of nitric oxide synthases (NOS). The effects of NO depend particularly 
on the actual NO concentration. At low concentrations, NO participates in many physiological 
processes, whereas high concentrations of NO, produced e.g. by the inducible NOS in the 
course of inflammatory diseases, initiate apoptosis and necrosis. 
PDGF, a potent growth factor, is able to counteract NO-production by inhibition of iNOS 
expression and activity. This work analyses the reciprocal control mechanisms of NO on the 
PDGF signalling system in rat glomerular mesangial cells (MC).  
In the first part of my work, the effect of NO on the expression of the PDGF ligands and their 
receptors was analysed. MC were stimulated with the NO delivering agent DETA-NO. 
PDGFR mRNA levels were analysed in polymerase chain reaction (PCR) for both receptor 
subunits. PDGFR-α mRNA expression was time- and dose-dependently induced by NO, 
whereas mRNA expression of the β-subunit was not significantly affected by DETA-NO. The 
time- and dose-dependent induction of PDGFR-α mRNA expression by NO could also be 
confirmed on the protein level by Western blotting. 
In the second part, the influence of endogenously produced NO on PDGFR-α -protein 
expression was investigated. MC were stimulated with the cytokine IL-1β, which is a known 
inducer of iNOS expression in rat MC. Consequently, IL-1β induces PDGFR-α expression. 
To discriminate between the IL-1β-iNOS-NO pathway and direct IL-1β mediated promoter 
activation, cells were costimulated with the NOS inhibitor L-NMMA. L-NMMA was not able 
to completely reverse the IL-1β mediated induction of PDGFR-α protein expression, but it 
diminished the effect significantly down to 60 %. This result reveals, that IL-1β involves 
iNOS activation to a certain degree for PDGFR-α induction.  
There are multiple mechanisms described for NO induced signalling. At subtoxic 
concentrations the most common pathway is mediated via activation of the soluble guanylyl 
cyclase (sGC). To examine whether NO uses the sGC pathway to induce PDGFR-α 
expression, DETA-NO stimulated MC were cotreated with the sGC inhibitor ODQ. ODQ 
reversed almost completely the NO-mediated effect. Additionally, MC were incubated with 
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dependently. Taken together both experiments indicate that the NO induced stimulation of 
PDGFR-α expression is due to sGC activation.  
Since NO affects many genes also on a transcriptional level, PDGFR-α promoter was cloned 
and promoter analysis was performed by the dual-luciferase reporter assay system. MC, 
transfected with a PDGFRα promoter/luciferase construct were stimulated with DETA-NO or 
with 8-Bromo-cAMP, a known inducer of PDGFR-α transcription. 8-Bromo-cAMP but not 
DETA-NO was able to induce PDGFR-α promoter transcription, indicating that the NO-
dependent stimulation of PDGFR-α expression is mediated posttranscriptionally or, 
alternatively, that the putative NO responsive element in the PDGFR-α promoter is not 
included in the cloned genomic DNA fragment. 
In the last part of my work, the functionality of NO on PDGFR-α expression was tested by 
analysis of the phosphorylation state of the α-receptor and of the downstream effector 
molecule protein kinase B (PKB). MC were prestimulated with DETA-NO and thereafter 
incubated for 15 min with PDGF-BB to activate the receptor. Western blot analysis, 
performed with anti-pTyr720-PDGFR-α-specific antibody, revealed that the NO-induced 
elevation of basal PDGFR-α protein level also increases PDGFR-α phosphorylation. 
Furthermore, an enhanced phosphorylation level of PKB was detected in DETA-NO 
pretreated cells, which were co-incubated with PDGF-AA, a PDGF isoform that selectively 
activates the PDGFR-α subunit.  
In co-operation with Dr. L. Schäfer (University of Münster), the NO-modulated induction of 
PDGFR-α expression was confirmed in an in vivo model of anti-Thy.1.1 nephritis. Inhibition 
of iNOS by the iNOS-specific inhibitor L-N
6-(1-iminoethyl)lysine (L-NIL) reduced PDGFR-
α expression as shown by immunohistochemistry and Western blot analysis.  
In conclusion, I have demonstrated that exogenously applied or endogenously produced NO 
induces the expression of PDGFR-α protein and that this increase permits enhanced 
phosphorylation of downstream effector molecules, which indicates that the actual amount of 
the receptor dictates the strength of the mitogenic effects of PDGF. NO induces the 
expression of PDGFR-α in vitro and in vivo. The pathophysiological significance of the NO-
mediated upregulation of PDGFR-α expression has yet to be clarified in further in vivo 
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V I I – S U P P L E M E N T 
 
7.1 Abbreviations 
 
ACE angiotensin  converting  enzyme 
8-Br-cAMP 8-bromo-adenine  monophosphate 
BFGF  basic fibroblast growth factor 
BSA  bovine serum albumin 
CDNA complementary  DNA 
CGMP  cyclic guanine monophosphate 
Co Control 
Crk chicken  tumour  virus no.10 regulator of 
kinases 
DETA-NO 1-[2-(2-Aminoethyl)-N-(2-ammonioethyl) 
amino] diazen-1-ium-1,2-diolate  
DMEM  Dulbecco’s modified Eagle’s medium 
DNA deoxyribonucleic  acid 
ECM extracellular  matrix 
E. coli  Escherichia coli 
ECL enhanced  chemiluminescence 
EGF  epidermal growth factor 
EDRF endothelial  derived relaxing factor 
et al.  et alter 
Fig Figure 
GAP  GTPase activating protein 
GAPDH Glyceraldehyde  3-phosphate dehydrogenase 
GBM glomerular  basement  membrane 
sGC  soluble guanylyl cycylase 
GF growth  factor 
GMC glomerular  mesangial  cell 
GN glomerulonephritis 
GFR  glomerular filtration rate 
H hour 
IκB inhibitor  of  κB 
IκB-K IκB-kinase 
IL-1β Interleukin  1-β 
IPTG isopropylthioglactoside 
KDa kilo  Dalton 
L-NIL L-N
6-(1-iminoethyl)lysine 
L-NMMA N
G-monomethyl-L-arginine 
Min minute 
mRNA messenger  RNA 
NF-κB nuclear  factor-κB 
NO nitric  oxide 
NOS, eNOS, iNOS, nNOS  nitric oxide synthase, endothelial NOS, 
inducible NOS, neuronal NOS 
OD optical  density 
ODQ 1H[1,2,4]oxadiazolo[4,3-a]-quinoxalin-1-one 
PBS phosphate-buffered  saline 
PCR  polymerase chain reaction VII – Supplement – Abbreviations                                                                                            - 82 - 
PDE phosphodiesterase 
PDGF  platelet-derived growth factor 
PDGFR  platelet-derived growth factor receptor 
pPDGFR phosphorylated  PDGF 
PI3-K Phosphatidylinositol  3’-kinase 
PKB  protein kinase B 
pPKB phosphorylated  PKB 
PKG  protein kinase G 
PLC-γ phospholipase  C-γ 
PVDF polyvinylidene  fluoride 
RNA ribonucleic  acid 
ROS  reactive oxygen species 
Rpm  Rounds per miniute 
RT reverse  transcriptase 
RTK  receptor tyrosine kinase 
SDS  sodium dodecyl sulfate 
Sec seconds 
SH-2  Src homology domain 2 
SPARC  secreted protein acidic and rich in cysteine 
STAT signal  transduction and activator of 
transcription 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TGF-β  transforming growth factor-β 
VEGF  vascular endothelial growth factor 
v/v  volume per volume 
w/v  weight per volume 
X-gal  5-bromo-4-chloro-3-indolyl-β-D-galactoside 
YC-1 3-5’Hydroxymethyl-2’-furyl-1benzylindazole 
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7.2 Zusammenfassung 
Stickoxid (NO) moduliert die Regulation des Plättchenwachstumsfaktorrezeptors α 
(PDGFR-α) in renalen Mesangiumzellen (MZ) der Ratte 
NO ist ein gasförmiges Molekül, das durch drei verschiedene NO-Synthasen hergestellt 
werden kann. Die Signalkaskaden von NO sind multipel und sehr stark von der jeweiligen 
Konzentration abhängig. In niedrigen Dosen ist NO an der Regulation physiologischer 
Prozesse beteiligt, wohingegen hohe NO-Spiegel, wie sie von der induzierbaren NO Synthase 
(iNOS) im Verlauf von entzündlichen Erkrankungen produziert werden, zytotoxische Effekte 
wie Apoptose und Nekrose bedingen können. Der Wachstumsfaktor PDGF kann durch 
Inhibition der iNOS Expression, dieser hohen NO Produktion entgegen wirken. Ob NO im 
Gegenzug auch eine Wirkung auf das PDGF-System aufweist, sollte mit dieser Arbeit geklärt 
werden. Da die Aktivität von PDGF letztendlich von der Rezeptormenge abhängt, wurde die 
expressionsmodulatorische Wirkung von NO auf der PDGF-Rezeptorebene untersucht. 
Im ersten Teil der Arbeit wurden MZ mit dem NO-Donator DETA-NO stimuliert. Mittels 
PCR-Analyse konnte gezeigt werden, dass NO die PDGFR-α-mRNA Expression zeit- und 
dosisabhängig induziert. Die Expression von PDGFR-β wird hingegen nicht wesentlich 
beeinflusst. Western-Blot-Analysen (WB) bestätigten die Regulierbarkeit des PDGFR-α auch 
auf Translationsebene. Als nächstes sollte geprüft werden, ob die durch exogene Applikation 
eines NO-Donatoren hervorgerufene Induktion des PDGFR-α auch durch eine endogene NO-
Produktion imitiert werden kann. Hierzu wurden MZ mit dem Zytokin IL-1β inkubiert. IL-1β 
steigert die iNOS und auch die PDGFR-α-Expression durch Induktion von 
Transkriptionsfaktoren. Die IL-1β bedingte PDGFR-α-Expression könnte dabei über zwei 
Mechanismen reguliert werden: Einerseits über die gesteigerte Synthese von NO durch iNOS 
und andererseits durch direkte Interaktionen der IL-1β-induzierten Transkriptionsfaktoren mit 
dem PDGFR-α-Promotor. Um die NO bzw. iNOS-vermittelte von der Promotor-vermittelten 
Wirkung zu unterscheiden, wurden MZ zusätzlich mit dem NOS-Inhibitor L-NMMA 
inkubiert. L-NMMA war im Stande die durch IL-1β hervorgerufene Erhöhung der PDGFR-α 
Proteinmenge signifikant auf 60% zu reduzieren, was die Beteiligung der iNOS bzw. von NO 
an der IL-1β vermittelten Regulation des PDGFR-α impliziert.  
NO entfaltet seine Wirkung über verschiedene Signalkaskaden. Der klassische Weg verläuft 
über die Aktivierung der löslichen Guanylatzyklase (sGC). Um die Beteiligung der sGC an 
der NO-vermittelten Induktion des PDGFR-α zu untersuchen, wurden DETA-NO stimulierte 
MZ zeitgleich mit ODQ, einem Inhibitor der sGC inkubiert. Die durch NO verursachte VII – Supplement – Zusammenfassung                                                                                    - 84 - 
Erhöhung der PDGFR-α-Proteinmenge konnte durch die gleichzeitige Zugabe von ODQ 
komplett gehemmt werden. Die Behandlung von MC mit dem sGC-Aktivator YC-1 imitierte 
andererseits den NO-Effekt. Beide Versuche zusammengenommen beweisen die 
Notwendigkeit der sGC-Aktivierung zur NO-vermittelten Induktion des PDGFR-α. 
Da viele Gene schon auf Transkriptionsebene durch NO beeinflusst werden, wurde der an 
einen Vektor gebundene PDGFR-α-Promotor vor das Luziferase-Gen kloniert und MZ mit 
diesem Konstrukt transfiziert. Die transfizierten MZ wurden mit DETA-NO oder 8-Bromo-
cAMP stimuliert. cAMP erhöht die Aktivität des PDGFR-α-Promotors und diente somit als 
Positivkontrolle. Die Promotoraktivität wurde indirekt über das Luziferase-Renilla-System 
bestimmt. Da NO im Gegensatz zu 8-Bromo-cAMP die Promotoraktivität nicht erhöhte, ist 
davon auszugehen, dass die NO-abhängige Induktion des PDGFR-α posttranskriptionell 
erfolgt oder, dass das NO-responsive Element nicht in unserem Konstrukt enthalten war.  
Im letzten Abschnitt meiner Arbeit wurde die Funktionsfähigkeit des neusynthetisierten 
PDGFR-α Proteins bestätigt. Hierzu wurde die Phosphorylisierung vom PDGFR-α und von 
einem weiteren in der PDGF-Signalkaskade angeordneten Enzym, der antiapoptotisch 
wirksamen Proteinkinase B (PKB) untersucht. Mit DETA-NO vorbehandelte MZ wurden mit 
PDGF-BB stimuliert und eine Nachweisanalyse mit einem Phospho-spezifischen Antikörper 
der gegen pTyr720-PDGFR-α (pPDGFR-α) gerichtet ist, durchgeführt. Der Vergleich mit 
nichtvorbehandelten MZ belegt eindeutig, dass die NO vermittelte Erhöhung der basalen 
PDGFR-α-Proteinmenge auch zu einer Zunahme an detektierbarem pPDGFR-α führt, die 
dann wiederum eine Verstärkung der Signaltransduktion zur Folge hat. So konnten in DETA-
NO vorbehandelten MZ, die mit dem α-Rezeptor spezifischen Liganden PDGF-AA stimuliert 
wurden, eine vergleichsweise erhöhte PKB-Phosphorylierung festgestellt werden.  
In einer Kooperation mit Dr. L. Schäfer (Universität Münster) konnte ferner gezeigt werden, 
dass die NO-Abhängigkeit der PDGFR-α Proteinexpression auch im Krankheitsverlauf eines 
experimentellen Glomerulonephritismodells, zu beobachten ist. Durch WB-Analysen und 
immunhistologischen Färbungen konnte dargelegt werden, dass die Vorinjektion des iNOS-
spezifischen Inhibitors L-NIL die Produktion von phosphoryliertem und unphosphoryliertem 
PDGFR-α Protein in Anti-Thy.1.1-behandelten Ratten signifikant hemmt.  
Zusammenfassend weisen die Ergebnisse darauf hin, dass NO über eine Aktivierung der sGC, 
die Produktion von funktionsfähigem PDGFR-α- Protein in vitro und in vivo steigert. Die 
pathophysiologische Bedeutung der NO-vermittelten Induktion des PDGFR-α im 
Krankheitsprozess der GN, wird gegenwärtig in weiteren in vivo Experimenten untersucht.VII – Supplement – Publication                                                                                              - 85 - 
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